[go: up one dir, main page]

WO2024083790A1 - Cellules dendritiques cd207 en tant que biomarqueur pour la progression tumorale et cible thérapeutique - Google Patents

Cellules dendritiques cd207 en tant que biomarqueur pour la progression tumorale et cible thérapeutique Download PDF

Info

Publication number
WO2024083790A1
WO2024083790A1 PCT/EP2023/078773 EP2023078773W WO2024083790A1 WO 2024083790 A1 WO2024083790 A1 WO 2024083790A1 EP 2023078773 W EP2023078773 W EP 2023078773W WO 2024083790 A1 WO2024083790 A1 WO 2024083790A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
tumour
cancer
cell
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/078773
Other languages
English (en)
Inventor
Florent GINHOUX
Charles-Antoine DUTERTRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Saclay
Original Assignee
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Saclay filed Critical Institut Gustave Roussy (IGR)
Priority to EP23793273.6A priority Critical patent/EP4605752A1/fr
Publication of WO2024083790A1 publication Critical patent/WO2024083790A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5759—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention proposes an efficient method to prognose the evolution of a solid cancer in a subject in need thereof, by analysing the frequency of a particular subset of dendritic cells as well as their relative number as compared to that of another subset of dendritic cells in a tumour sample of said subject. More precisely, the method of the invention comprises the step of detecting and quantifying the frequency of CD207 conventional dendritic cells of type 2 and 3 (“CD207 + DC2+DC3”) in a tumour sample of said subject. If the frequency of said cells is high, in particular in the tumour core, then it means that the subject has a bad prognosis.
  • the method of the invention also comprises the calculation within the tumour of the ratio of the number of conventional dendritic cells of type 1 (cDCl) to the number of CD207 + DC2+DC3 to predict T-cell clonality in the tumour.
  • cDCl conventional dendritic cells of type 1
  • CD207 + DC2+DC3 participate in the regulation of the anti -tumour T-cell cytotoxicity by limiting T-cell clonality and impairing the CD8 + tissue resident memory T cell (TRM) response.
  • TRM tissue resident memory T cell
  • Their analysis furthermore reveals that the CD207 + DC2+DC3 are enriched in biopsies from later deceased patients as compared to alive patients suffering from different solid cancers.
  • the inventors also propose to reduce the abundance of these cells within the tumour core, e.g., by appropriate drugs, in order to limit the development of said solid tumour in the subject.
  • the mononuclear phagocyte system was initially comprised of monocytes and macrophages, which later included conventional dendritic cells (eDCs) discovered by Ralph Steinman and colleagues (Steinman and Cohn, 1973). These cells were shown to be the unique potent activators of naive T-cells and were viewed as ‘accessory’ cells bridging the innate and adaptive immune response (Nussenzweig et al., 1980; Steinman and Witmer, 1978; Steinman et al., 1983).
  • CDPs common DC progenitors
  • CD123 + DCs were shown to harbour both bona fide pDCs and DC precursors (pre-DCs) (See et al., 2017; Villani et al., 2017).
  • CDlc + “cDC2s” were shown to comprise CD5 + cDC2s and a subset of CD5 CD14 +/ ' DC3, the latter of which has been shown to expand during inflammation (Bourdely et al., 2020; Dutertre et al., 2019). Whether DC3s belong formally to the eDC lineage through a shared development from the common DC progenitor (CDP)/pre-DCs still remains an open and important question. Indeed, recent studies showed that DC3s could derive directly from a GMP/MDP progenitor, independently of CDPs/pre-DCs (Bourdely et al., 2020; Cytlak et al., 2019).
  • One example is the mature DCs enriched in immunoregulatory molecules (mregDCs), which have been recognized as terminally differentiated and matured states of cDCls, DC2s and potentially DC3s, and are implicated in tumour immunity (Di Pilato et al., 2021; Maier et al., 2020; Zheng et al., 2017).
  • DC3 was initially coined to describe a subset of inflammatory CD5 CD14 +/ ' CDlc + mDCs (Bourdely et al., 2020; Cytlak et al., 2019; Dutertre et al., 2019), whereas others have used this term to describe cells (Di Pilato et al., 2021; Gerhard et al., 2020; Zilionis et al., 2019) that have an obvious transcriptomic alignment to mregDCs (Maier et al., 2020).
  • CD207 + (Langerin) population has been described in various contexts (Bell et al., 1999; Leader et al., 2021; Zhang et al., 2021). Evidently, there is little consensus on how these subsets are characterised, which confuses both experts and new researchers entering the field (Ginhoux et al., 2022). In this context, there is a need to clarify and ascertain which subtype of dendritic cells is involved in the pathogenicity of solid cancers.
  • TILs tumour-infiltrated lymphocytes
  • CD207 DC2+DC3s or “CD207 + DC2+DC3s” in various solid tumours.
  • Spatial transcriptomics from human breast cancers have shown in the past that these cells localised within the tumour stromal region, contrary to most other immune cells. This observation complemented previous findings, where these cells had a high number of interactions with fibroblasts (Kim et al., 2020).
  • Figure 2 rather show that CD207 + DC2+DC3s in fact specifically accumulate within the tumour core, more precisely within the tumour glandular areas of solid tumour, surprisingly far away from the B and T lymphocytes that rather accumulate in the tumour stroma.
  • the inventors demonstrate that these particular cells are mainly enriched in patients without T-cell clonal expansion, contrary to mregDCs and cDCls that behave oppositely.
  • the inventors herein show that a common state of DC2+DC3s that co-expressed CD207 and CDla (CD207 + DC2+DC3) (1) accumulate inside the tumour of most cancer studied; (2) inversely correlate with T-cell clonal expansion, and with the frequency of CD8 + resident memory T-cells (TRMS, that are classically defined as co-expressing CD69 and CD 103); (3) are mostly detected embedded within tumour nests while all the other DCs, T and B cells were mainly detected within the tumour stroma of breast and lung adenocarcinomas.
  • CD8 + TRM -cells that are classically defined as co-expressing CD69 and CD 103 which are known to accumulate in various cancers and are associated with improved disease outcomes and survival (Park et al., 2019).
  • CD207 DC2+DC3s on the contrary strongly positively correlated with terminally differentiated effector memory T-cells that re-express CD45RA (hereafter “CD8 + TEMRA cells”), which have been shown to be senescent/hypofunctional cells (Reading et al., 2018).
  • CD207 DC2+DC3s could participate in the regulation of the anti -tumour T-cell cytotoxicity, for example by limiting T-cell clonality in the tumour core. They therefore propose to use the CD207 DC2+DC3s signature to predict T-cell clonality within solid tumours.
  • High T-cell clonality being a sign of good prognostic for a patient suffering from a solid tumour
  • the inventors finally analysed the Disease-Specific Survival (DSS) of patients, depending on the presence or not of high levels of CD207 DC2+DC3 in their tumour core. They observed that, surprisingly, high levels of CD207 DC2+DC3 in tumour nests associate with cancer-related deaths in all the seven TCGA cancer datasets analysed as compared to alive patients ( Figure 3F) and in other independent cohorts of patients (Figure 3G).
  • DSS Disease-Specific Survival
  • CD207 DC2+DC3s could also serve as a prognostic factor by calculating the ratio between the number of CD207 DC2+DC3s with respect to the number of cDCls within the tumour core, as their results show that this ratio predicts efficiency and reliably whether patients would develop a T-cell clonal expansion ( Figure 3B).
  • the CD207 DC2+DC3s to cDCls ratio is also proposed as a reliable mean to predict the progression of solid tumours.
  • the present inventors have surprisingly found that solid tumours display a higher proportion of a specific class of dendritic cells, namely CD207 + conventional dendritic cells of type 2 and 3 (DC2+DC3).
  • the present inventors have found that the population of DC2+DC3 dendritic cells expressing the biomarkers CD207 and CD la (the so-called CD207 + DC2+DC3) are hyperrepresented in the tumour core of patients suffering from a severe cancer associated with bad prognosis.
  • the proportion of this population of dendritic cells in the tumour core of these patients is much higher than in the stroma of said tumour or in the tumour core of patients suffering from a cancer with good prognosis.
  • CD207 + DC, DC1 and mregDC which evaluate the predictive impact of the expression of genes specifically expressed by dendritic cell subpopulations (CD207 + DC, DC1 and mregDC) on the survival of patients with a broad spectrum of solid tumors who received therapeutic antibodies (anti-PD-1, PD-L1 or CTLA4)
  • the proportion of CD207 + DC2+DC3 is sufficient to discriminate between numerous cancer patients having a good versus a bad prognosis. Therefore, the high frequency of CD207 + DC2+DC3 in the tumour core can be used as a negative prognosis factor for a number of solid cancers.
  • the invention thus enables the skilled person to identify those subjects suffering from a solid cancer will have a short survival, simply by quantifying the frequency of CD207 DC2+DC3 in a tumour sample from said subjects.
  • a unique and rapidly obtained parameter is used in the method of the invention. This parameter can be determined in few hours, when flow cytometry is used.
  • flow cytometry When immunohistochemistry is used, it is possible to obtain the prognosis in about two days’ time.
  • RNAseq is used, the timing is longer (at least two weeks) but it is always less than the current 3 months required by the methods involving single-cell TCR- sequencing.
  • the method of the invention is particularly advantageous because it generates a prognosis in a very short time and with a very high degree of confidence, whereas the method currently recommended by WHO (single-cell TcR-sequencing) is both time-consuming and costly.
  • the present invention thus provides an in vitro method to prognose the evolution of a solid cancer in a subject in need thereof or to monitor or follow-up the evolution of a solid cancer, or for determining the outcome of a solid cancer.
  • Said method comprises the steps of: a) Detecting and quantifying the quantity, density or frequency of CD207 + conventional dendritic cells of type 2 (DC2+DC3) cell population in a tumour sample of said subject, b) Comparing the value of step a) to a reference value, and c) Prognosing that the subject has a bad prognosis if the quantity, density or frequency of CD207 + DC2+DC3 cell population is higher than said reference value.
  • the CD207 + conventional dendritic cells of type 2 (DC2+DC3) are herein called “dendritic cells of the invention”. These cells are dendritic cells expressing high level of CD la and CD207 proteins or high level of CD1A and CD207 transcripts (mRNAs).
  • the sequence of the cluster of differentiation CD la is well-known.
  • This member of the CD1 family is a transmembrane glycoprotein that is structurally related with the major histocompatibility Complex (MHC) proteins and forms heterodimers with the 0-2- microglobuline.
  • MHC major histocompatibility Complex
  • the protein has the sequence displayed in NP OO 1307581 and NP_001754, encoded by the NM_001763 and NM_001320652 mRNAs.
  • Antibodies recognizing CD la are commercially available. They can be used for ELISA, flow cytometry, IHC, and western-blots.
  • the CD207 marker is also called Langerin. It is a type II transmembrane protein expressed by Langerhans cells and dendritic cells. Langerin recognizes and binds carbohydrates, such as mannose, fucose and N-acetylglucosamine. It contributes to the binding of the antigen to CD la molecule. In mice, langerin is involved in antigen binding to MHC II glycoproteins and to MHC I glycoproteins during cross-presentation. In human, the protein NP 056532 is encoded by NM_015717 mRNA. Antibodies recognizing Langerin are commercially available. They can be used for ELISA, flow cytometry, IHC, and western-blots.
  • the term “tumour sample” or “solid cancer sample” means a sample containing a detectable amount of tumour cells. Such solid cancer sample allows the skilled person to perform any type of measurement of the level of the dendritic cells of the invention.
  • the methods according to the invention may further comprise a preliminary step of taking a solid cancer sample from the patient.
  • a solid cancer sample it is referred to a tumour tissue sample. Even in a cancerous patient, the tissue which is the site of the tumour still comprises non tumour healthy tissue.
  • the “cancer sample” should thus be limited to tumour tissue taken from the patient.
  • Said “cancer sample” may be a biopsy sample or a sample taken from a surgical resection therapy.
  • samples are preferably maintained in appropriate conditions so that they are not altered after their collect from the subject’s body.
  • isolated cells can be maintained in freezing conditions and / or suspended immediately analysed by flow cytometry to evaluate their frequency among CD45 + leukocytes.
  • the cancer sample can be embedded in paraffin or snap-frozen followed by analysis of CD207 + cells by immunohistochemistry.
  • the tissue is a diseased tissue.
  • the tissue is a tumour or a biopsy thereof.
  • a tissue or a biopsy thereof is first excised from a patient, and the levels of the cells of the invention in the tissue or biopsy are then determined in an immunoassay with the antibodies or antibody fragments described below.
  • step a) of the method of the invention is achieved by flow cytometry by assessing the relative frequency of CD207 + DC2+DC3 cells among CD45 + leukocytes on a sample of the tumour, preferably on a sample of the tumour core.
  • Flow cytometry is a powerful technology that allows researchers and clinicians to perform complex cellular analysis quickly and efficiently by analysing several parameters simultaneously.
  • the amount of information obtained from a single sample can be further expanded by using multiple fluorescent reagents.
  • the information gathered by the flow cytometer can be displayed as any combination of parameters chosen by the skilled person.
  • Cells pass single-file through a laser beam. As each cell passes through the laser beam, the cytometer records how the cell or particle scatters incident laser light and emits fluorescence. Using a flow cytometric analysis protocol, one can perform a simultaneous analysis of surface molecules at the single-cell level.
  • the detection of the cell surface antigens in the methods of the invention is performed by an exclusion gating strategy by flow cytometry.
  • the step a) of the invention requires to exclude the contaminant cells from the population of dendritic cells type 2 and 3 expressing CD207 and CD la.
  • contaminant cells refer to granulocytes, e.g. neutrophils, eosinophils, basophils, mast cells, monocytes, macrophages and lymphocytes, e.g., T cells, NK cells, ILCs, B cells, but also precursors of these cell types.
  • neutrophils e.g. neutrophils, eosinophils, basophils, mast cells, monocytes, macrophages and lymphocytes, e.g., T cells, NK cells, ILCs, B cells, but also precursors of these cell types.
  • the existence of markers which are specific for each of the contaminant cell types enables the identification of these cells in the sample of the subject. Identified contaminant cells can then be removed from the sample (i.e., physically) or from the analysis (i.e., by retaining only the data pertaining to the dendritic cell population for the analysis), so that the study then only focuses on the dendritic cell population.
  • any of the above-mentioned analytical techniques can be used to identify the said contaminant cells, flow cytometry is particularly adapted for this task, since it enables the skilled person to eliminate the contaminants and analyse the dendritic cell population with minimal effort.
  • any antibodies directed against one or more antigens expressed by one or more of the contaminant cells can be used to identify the said contaminant cells.
  • antibodies specific for well-known antigens expressed by granulocytes (CD 15, CD 16), T lymphocytes (CD3), B lymphocytes (CD 19), and/or NK cells (CD 16) can be used in step a).
  • anti-CD15, anti-CD16, anti-CD3 or anti-CD19 antibodies therefore enables to detect and therefore exclude the cells expressing CD15, CD16, CD3 and CD19 proteins, notably the CD3 + T lymphocytes, the CD16 + NK cells, as well as the CD15 + or CD16 + granulocytes.
  • the antibodies used to identify and/or to remove the contaminant cells according to the method of the invention comprise anti-CD15, anti-CD16, anti-CD3, and anti- CD19 antibodies.
  • anti-CD15 antibodies may be used instead of anti-CD16 antibodies to detect the granulocytes.
  • Cells expressing CD45 at their surface are all human leucocytes (more precisely, lymphocytes, eosinophils, monocytes, basophils and neutrophils, and dendritic cells with different level of expression). This cluster of differentiation is however absent from erythrocytes and platelets.
  • the dendritic cells are detected in the CD45 + population of the cells present in the tumour sample. After exclusion of other contaminating populations, the expression level of CDla and/or CD207 can be assessed (see Figure 6).
  • the first step of the method of the invention comprises the detection and the measurement of CD45 expression at the cell surface of the cells present in the tumour sample.
  • the sequence of the cluster of differentiation CD45 is well-known.
  • the CD45 molecules are single chain integral membrane proteins, comprising at least 5 isoforms, ranging from 180 to 220 kDa. They are generated by alternative splicing combinations of three exons (A, B, and C) of the genomic sequence.
  • the non-restricted CD45 antigen, Leucocyte Common Antigen (LCA) consists of an extracellular sequence, proximal to the membrane, which is common to all CD45 isoforms. All the monoclonal antibodies that belong to the CD45 cluster react with this part of the antigen and are able to recognize all CD45 isoforms.
  • These isoforms have extra-cytoplasmic sequences ranging from 391 to 552 amino acids long, with numerous N-linked carbohydrate attachment sites. The cytoplasmic portion contains two phospho-tyrosine-phosphatase domains.
  • the DC2+DC3 cells of the invention are more precisely identified by flow cytometry as proposed on Figure 6, i.e., by selecting live cells, then CD45 + cells, then, among these CD45 + cells, CD3 CD16 CD19 CD20" cells that are also HLA-DR + , then, among these CD3 CD16 CD19 CD20" HLA-DR + cells, the cells that are CD 14" CDlc + CDla + and CD207 + .
  • step a) of the method of the invention is performed by flow cytometry, preferably by measuring the expression of CD3, CD 16, CD 19, CD20, CD 14, HLA- DR, CDlc, CD la and CD207 biomarkers at the surface of the CD45 + leukocytes, in order to detect the frequency of the DC2+DC3 cells of the invention among CD45 + leukocytes.
  • the use of fluorochrome agents attached to anti-CD45, anti-CD3, anti-CD16, anti-CD19, anti-CD20, anti-CD14, anti-CDlc, anti-CD207, anti-CDla, anti- CADM1 and/or anti-CD141 antibodies to enable the flow cytometer to analyse on the basis of size, granularity and fluorescent light is highly advantageous.
  • the flow cytometer can be configured to provide information about the relative size (forward scatter or “FSC”), granularity or internal complexity (side scatter or “SSC”), and relative fluorescent intensity of the cell sample.
  • FSC forward scatter
  • SSC side scatter
  • the fluorescent light determines CD45-expressing, CD3, CD16, CD19, CD20 nonexpressing cells but HLA-DR, CDlc, CD207 and CD la -expressing cells as being “CD207+CDla+ dendritic cells” (DC2+DC3).
  • the fluorescent light determines CD45 -expressing, CD3, CD16, CD19, CD20, CDlc, CD14 non-expressing but HLA-DR, CADM1, and CD141 -expressing cells as being “dendritic cells type 1 (cDCl)”.
  • the tumour core is determined by the surgeon during the surgery.
  • the samples can be washed with appropriate buffers in order to separate the cells and permit the proper binding of the antibodies to the surface markers.
  • the expression of the cell surface antigens may also be assessed using well known technologies such as cell membrane staining using biotinylation or other equivalent techniques followed by immunoprecipitation with specific antibodies, flow cytometry, western blot, ELISA or ELISPOT, antibodies microarrays, or tissue microarrays coupled to immunohistochemistry.
  • FRET FRET
  • BRET single cell microscopic or histochemistry methods using single or multiple excitation wavelength
  • electrochemical methods voltametry and amperometry techniques
  • atomic force microscopy e.g.
  • multipolar resonance spectroscopy confocal and non-confocal, detection of fluorescence, luminescence, chemiluminescence, absorbance, reflectance, transmittance, and birefringence or refractive index (e.g., surface plasmon resonance, ellipsometry, a resonant mirror method, a grating coupler waveguide method or interferometry), cell ELISA, radioisotopic, magnetic resonance imaging, analysis by polyacrylamide gel electrophoresis (SDS-PAGE); HPLC-Mass Spectroscopy; Liquid Chromatography/Mass Spectrometry/Mass Spectrometry (LC-MS/MS)).
  • step a) of the method of the invention requires assessing the frequency or the density of CD207 + DC2+DC3 by immunohistochemistry on a sample of the tumour, preferably on a sample of the tumour core.
  • Immunohistochemistry is a well-known technique.
  • FFPE paraffin
  • Immunostainings can be performed on 3 pm thick whole sections prepared from FFPE blocks of tumour, as disclosed in the examples below.
  • tumour core can be easily visually identified on the embedded tissue by an anatomo- pathologist following haematoxylin and eosin chemical staining.
  • the identification of the DC2+DC3 dendritic cells of the invention and the determination of their density is made by immunohistochemistry, automatically, by using an anti-CD207 antibody only.
  • the method of the invention uses an anti-CD207 antibody and an anti-CLEC9A (and/or anti-XCRl) antibody, in order to automatically quantify by immunohistochemistry the density or the frequency of DC2+DC3 and of cDCl cells, respectively, and be able to calculate the ratio of the invention (see below for more details).
  • step a) of the method of the invention is performed by measuring the expression level of the CD1A and CD207 genes in a nucleotide sample of the tumour, preferably in a RNA sample of the tumour core by measuring the quantity of CD1A and CD207 mRNAs present in same. It is also possible to measure the expression level of the HLA DQB2 gene in the nucleotide sample of the tumor (for example by quantifying the amount of HLA DQB2 mRNA), in order to confirm the result provided by the expression levels of the two other genes.
  • nucleotide sample means a sample containing a detectable amount of RNA extracted from the cells of interest.
  • the nucleotide sample may be obtained from any tumour sample, and, in particular, from a biopsy of a tumour tissue.
  • the method of the invention can include the steps consisting of obtaining a tumour sample (e.g., a tissue biopsy) from said subject and extracting the nucleotide fraction from said tumour sample.
  • the nucleotide fraction can be extracted using any known method in the state of the art.
  • the skilled person well knows how to prepare a tumour sample (that has been previously collected and stored under appropriate freezing conditions) in order to be used in gene analysis.
  • the samples are washed with appropriate buffers and put in a lysis buffer so as to isolate the RNA.
  • RNA is preferably extracted from said sample by using a convenient commercial extraction protocol such as those proposed by MOBIO, Qiagen or Zymo.
  • tumour nucleotide sequence designates the sequence of the oligonucleotides contained in a tumour sample. Preferably, this sample contains all the mRNAs present in the tumour sample.
  • the expression level of the target genes is preferably measured by RT-qPCR or by RNAseq.
  • RT- qPCR is a well-known technology whose conditions are thoroughly explained in the notice of commercial kits (SIGMA- ALDRICH, QIAGEN, ... ).
  • RNAseq is the preferred technology to assess the expression levels of the genes CD207 and CD1A in a nucleotide sample of the tumor.
  • the level of CD207 + DC2+DC3 cells in the tumour sample can give a quantitative score of the CD8 TRM-cells infiltration in the region of interest. Also, this level can be used to measure the clonal proliferation of CD8 T cells within the tumour, which is inversely correlated to the level of CD207 DC2+DC3 cells in the tumour sample.
  • the frequency of CD207 + DC2+DC3 is increased in a sample of the tumour core, preferably in the glandular structure of the tumour nest, as compared to the reference value, then this means that the prognosis of the subject is bad.
  • bad prognosis it is herein meant that the outcome of the tested patient is likely to be a short survival, typically a survival of less than one year, two years, or five years. Patients having such Overall Survival is also called a “bad responder” if the patient was receiving a therapy.
  • good prognosis it is herein meant that the outcome of the tested patient is likely to be a long survival, typically longer than 5 years, or more than 7 years.
  • the absolute frequency of CD207 DC2+DC3 present in the tumour sample of the subject may be used to determine the prognosis of said cancer.
  • this ratio enables to precisely predict the T-cell clonality in the tumour.
  • the present invention encompasses a method to prognose the evolution of a solid cancer in a subject in need thereof, said method comprising the steps of: a) Detecting and quantifying the quantity, density or frequency of CD207 + conventional dendritic cells of type 2 (DC2+DC3) cell population as defined above, in a tumour sample of said subject, b) Detecting and quantifying the quantity, density or frequency of conventional dendritic cells of type 1 (cDCl) cells in the same tumour sample, c) Comparing the value of step a) to the value obtained in step b), and d) Prognosing that the subject has a bad prognosis if the quantity, density or frequency of CD207 + DC2+DC3 cell population is higher than the quantity, density or frequency of cDCl cells.
  • the detection and quantification of the cells can be performed by any of the conventional means proposed above.
  • said steps a) and b) are performed by exclusion gating flow cytometry.
  • CD207 + DC2+DC3 cells can be identified as proposed above (see also Figure 6).
  • cDCl cells are dendritic cells expressing high level of CD 141, CADM1, CLEC9A, XCR1, BTLA. All these markers are well known. By flow cytometry, cDCl cells can be detected by identifying the CD45 + CD3' CD16 CD19’ CD20’ CD14’ CDlc CD141 + CADM1 + cells.
  • the cDCl cells can be identified by flow cytometry by selecting live cells within the tumour cells, then CD45 + cells, then, among these CD45 + cells, CD3 CD16 CD19 CD20" cells that are also HLA-DR + , then, among these CD3 CD16 CD19 CD20' HLA-DR + cells, the cells that are CD14’ CDlc CD141 + and CADM1 + . All these markers are well known.
  • the detection and quantification of the CD207 + DC2+DC3 cells and of the cDCl cells can alternatively be performed by any of the conventional means described above.
  • said steps a) and b) are performed by immunohistochemistry.
  • the CD207 + DC2+DC3 cells can be identified as proposed above.
  • cDCl cells they can be easily identify by immunohistochemistry by using either anti-XCRl antibodies, or anti-CLEC9A antibodies, or both antibodies.
  • said steps a) and b) are performed by RNAseq.
  • the quantification of the DC2+DC3 cells can also be done by measuring the mRNA levels of the CD207 gene and/or of the CD1A gene.
  • the quantification of the cDCl cells can be done by measuring the mRNA levels of the ACV?/ gene and/or of the CLEC9A gene.
  • the steps c) and d) of this method are replaced by the calculation of a ratio between the quantity, density or frequency of CD207 + DC2+DC3 cells present in a sample of a solid tumour and the quantity, density or frequency of cDCl cells present in said sample.
  • the ratio may involve the calculation of the density of CD207 + DC2+DC3 present in a sample of a solid tumour and the density of cDCl cells present in said sample, both densities being detected by immunohistochemistry by using anti-CD207 antibodies (for detecting DC207 + DC2+DC3 cells) and anti-CLEC9A or antiXCRl antibodies (for detecting cDCl cells).
  • the ratio may involve the calculation of the frequency of CD207 + DC2+DC3 present in a sample of a solid tumour and the frequency of cDCl cells present in said sample, both frequencies being detected by flow cytometry by using the antibodies mentioned above for detecting DC207 DC2+DC3 cells and cDCl cells by flow cytometry.
  • the ratio may involve the calculation of the amount of CD207 + DC2+DC3 present in a sample of a solid tumour and the amount of cDCl cells present in said sample, both amounts being measured by RNAseq by measuring for example the mRNA level of the CD207 gene (for detecting DC207 + DC2+DC3 cells) and the mRNA level of the AC7 / gene (for detecting cDCl cells).
  • the ratio CD207 + DC2+DC3 / cDCl cells is superior or equal to 1, then the prognosis of said cancer is bad. If said ratio is inferior to 1 , then the prognosis of said cancer is good.
  • this ratio allows to evaluate and predict the level of T-cell clonality in the tumour.
  • the ratio CD207 + DC2+DC3 / cDCl cells is superior or equal to 1, then the T-cell clonality in said tumour is low. If said ratio is inferior to 1, then the T-cell clonality in said tumour is high.
  • the steps c) and d) are replaced by the calculation of a ratio between the quantity, density or frequency of cDCl cells present in a sample of a solid tumour and the quantity, density or frequency of CD207 + DC2+DC3 cells present in said sample.
  • the ratio cDCl / CD207 + DC2+DC3 is inferior to 1, then the prognosis of said cancer is bad. If said ratio is superior or equal to 1 , then the prognosis of said cancer is good.
  • the ratio cDCl / CD207 + DC2+DC3 is superior or equal to 1, then the T-cell clonality in said tumour is high. If said ratio is inferior to 1, then the T-cell clonality in said tumour is low.
  • the present invention targets the use of the ratio between the quantity, density or frequency of CD207 + DC2+DC3 cells present in a sample of a solid tumour and the quantity, density or frequency of cDCl cells present in the same sample of solid tumour (or vice versa) to prognose the evolution of a solid cancer or the T-cell clonality in the tumour.
  • This frequency is preferably obtained by exclusion gating flow cytometry, whereas the density is preferably obtained by immunohistochemistry and the quantity of the cells by RNAseq.
  • bad prognosis it is herein meant that the outcome of the tested patient is likely to be a short survival, typically a survival of less than one year, two years, or five years. Patients having such Overall Survival is also called a “bad responder” if the patient was receiving a therapy.
  • good prognosis it is herein meant that the outcome of the tested patient is likely to be a long survival, typically longer than 5 years, or more than 7 years.
  • the method of the invention can be used to predict the outcome of cancer patients. In a preferred embodiment, it is used to aid the skilled cancerologist in the selection of appropriate treatments for maximizing the survival of the patients. Appropriate treatments are for example chemotherapeutic treatments, immunotherapeutic treatments, radiotherapeutic treatments and/or surgery. Preferably, the signature of the invention is generated before initiating a treatment.
  • said patients have been treated or will be treated with anti-cancer drugs as defined below.
  • the present prognostic tool may also assist physicians in identifying patients who are likely to progress towards even more serious form of solid cancer and thus may suggest those patients require heavier or more aggressive treatment.
  • the methods of the invention furthermore enable to generate a personalized treatment plan.
  • the personalized treatment plan is based on the high or low level of the cells of the invention in the tumour sample.
  • the personalized treatment plan may include a new therapeutic recommendation, a new therapeutic schedule, a new therapeutic dosage, a follow up treatment schedule, or other action.
  • the personalized treatment plan may include information that facilitates developing a precision treatment plan for a patient. For example, upon determining that a tumour is classified as a responder, the method of the invention may control the personalized cancer treatment system to generate a first personalized treatment plan that indicates a first type of therapy. Upon determining that the tumour is classified as a nonresponder to this first therapy, the method may generate a second, different personalized treatment plan that proposes a second, different type of therapy.
  • the methods of the invention produce the concrete, real-world technical effect of reducing the amount of unnecessary biopsies or other invasive procedures for patients who are unlikely to benefit from immunotherapy treatment. Additionally, these methods reduce the expenditure of time, money and therapeutic resources on patients who are unlikely to benefit from the treatment. They thus improve on conventional approaches to predicting response to therapy in a measurable, clinically significant way.
  • the methods of the invention can be used: to evaluate the response of a patient to an anti-cancer treatment, to select an anti-cancer therapy for a patient, to assess the efficacy of an anti-cancer therapy for a patient, to adapt an anti-cancer therapy for a patient and/or to identify if a tumour or a patient is responding to the therapy,
  • the invention pertains to in vitro methods for selecting an anti-cancer therapy for a patient suffering from a solid cancer, said methods comprising the steps of: a) performing the prognostic methods of the invention, as defined above, before and after a candidate anti-cancer therapy has been administered to the patient, b) selecting said therapy if the level of CD207 DC2+DC3 cells has significantly decreased or if the ratio between CD207 + DC2+DC3 cells and cDCl cells has diminished, after the therapy was given.
  • the invention pertains to in vitro methods for assessing the efficacy of an anti-cancer therapy in a patient suffering from a solid cancer, said methods comprising the steps of: a) performing the prognostic methods of the invention, as defined above, before and after a candidate anti-cancer therapy has been administered to the patient, and b) concluding that said therapy is efficient or that the tumour is responding to said therapy if the level of CD207 + DC2+DC3 cells has significantly decreased or if the ratio between CD207 + DC2+DC3 cells and cDCl cells has diminished, after the therapy was given, or c) concluding that said therapy is not efficient or that the tumour is not responding to said therapy if the level of CD207 + DC2+DC3 cells has significantly increased or if the ratio between CD207 + DC2+DC3 cells and cDCl cells has increased, after the therapy was given.
  • the invention pertains to in vitro methods for adapting an anti-cancer therapy in a patient suffering from a solid cancer, said methods comprising the steps of: a) performing the prognostic methods of the invention, as defined above, before and after a candidate anti-cancer therapy has been administered to the patient, b) concluding that said therapy is efficient or that the tumour is responding to said therapy if the level of CD207 + DC2+DC3 cells has significantly decreased or if the ratio between CD207 + DC2+DC3 cells and cDCl cells has diminished, after the therapy was given, and maintaining same, c) concluding that said therapy is not efficient or that the tumour is not responding to said therapy if the level of CD207 + DC2+DC3 cells has significantly increased or if the ratio between CD207 + DC2+DC3 cells and cDCl cells has increased, after the therapy was given, and therefore changing same.
  • said adaptation of the anti-cancer therapy may consist in: • the continuation, a reduction or suppression of the said therapy if the therapy has been assessed as efficient, or adapted to said “responder” tumour, or if the prognosis is sufficiently good.
  • the response to a therapy is preferably defined according to RECIST 1.1 criteria.
  • a Complete Response (CR) is defined as a disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to ⁇ 10 mm.
  • a Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
  • a Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
  • a Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
  • a “non-responder” is considered as a patient with a progression disease or a stable disease as defined according to RECIST 1.1 criteria.
  • the present invention targets the use of the ratio between the amount, the density or the frequency of CD207 + DC2+DC3 cells present in a sample of a solid tumour and the amount, the density or the frequency of cDCl cells present in the same sample of solid tumour to evaluate the response of a patient to an anti-cancer treatment, to select an anti-cancer therapy for a patient, to assess the efficacy of an anti-cancer therapy for a patient, to adapt an anti-cancer therapy for a patient, to identify if a tumour or a patient is responding to the therapy, or to generate a personalized treatment plan, as explained above.
  • the present inventors propose to target cytotoxic agents to the CD207 + DC2+DC3 cells in order to deplete or destroy them and to increase the level of T CD8 + within the tumour, thereby increasing the prognosis of the patients and eventually treat them.
  • Said agent can be, for example, bicyclic peptides, antibodies, or antibody fragments like diabodies, Fab, or scFV.
  • the present invention proposes a cytotoxic antibody that specifically binds to CD207 + DC2+DC3 cells of the invention, for use for depleting said cells from the tumour core of a solid tumour.
  • antibody of the invention can be a chimerized or a humanized antibody, as defined below. It can be multispecific, and in particular bispecific. As such, it can be chosen in the group consisting of: bispecific IgGs, IgG-scFv2, (scFv)4-IgG, (Fab')2, (scFv)2, (dsFv)2, Fab-scFv fusion proteins, (Fab-scFv)2, (scFv)2-Fab, (scFv-CH2-CH3-scFv)2, bibody, tribody, bispecific diabody, disulfide-stabilized (ds) diabody, 'knob-into whole' diabody, singlechain diabody (scDb), tandem diabody (TandAb), flexibody, DiBi miniantibody, [(scFv) 2-Fc] 2, (scDb-CH3)2, (scDb-Fc)2,
  • the cytotoxic agent of the invention is an antibody that specifically binds to the CD207 protein located at the surface of CD207 + DC2+DC3.
  • Bispecific antibodies targeting the CD207 protein can also be used.
  • Bispecific antibodies targeting the CD la and the CD207 (Langerin) protein can also be used. This cytotoxic antibody would preferably bind with high affinity and specificity dendritic cells that express high levels of CD la and CD207 biomarkers. These biomarkers have been described above.
  • the antibodies of the invention have a high affinity for CD207. More preferably, they possess a very low dissociation constant with these receptors. For example, a low dissociation constant is inferior or equal to 50 nM and may reach down to the picomolar range (10‘ 12 M). More specifically, the antibodies of the invention or antigen-binding fragments thereof have a dissociation constant (KD) with CD207 comprised between about 5 nM and about 20 nM as measured by Surface Plasmon Resonance.
  • KD dissociation constant
  • the antibodies of the invention would be preferably conjugated to a potent cytotoxic compound such as a radioisotope, a chemotherapeutic drug or a toxin, so as to provide an “Antibody-Drug Conjugate” (ADC). Examples thereof are given below.
  • the antibodies of the invention comprise changes in amino acid residues in the Fc region that lead to improved effector function including enhanced complement-dependent cytotoxicity (CDC) and/or antibody-dependent cellular cytotoxicity (ADCC) function and eventually DC-cell killing (also referred to herein as DC-cell depletion).
  • CDC complement-dependent cytotoxicity
  • ADCC antibody-dependent cellular cytotoxicity
  • DC-cell killing also referred to herein as DC-cell depletion
  • three mutations have been identified for improving CDC and ADCC activity: S298A/E333A/K334A (also referred to herein as a triple Ala mutant or variant; numbering in the Fc region is according to the EU numbering system). This may be achieved by introducing one or more amino acid substitutions in an Fc region of an antibody.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • FcRs Fc receptors
  • cytotoxic cells e.g., Natural Killer (NK) cells, neutrophils, monocytes and macrophages
  • NK cells Natural Killer cells
  • monocytes express Fc[gamma]RI, Fc[gamma]RII and Fc[gamma]RIII.
  • an in vitro ADCC assay such as that described in U.S. 5,500,362 or 5,821,337 can be performed.
  • Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
  • PBMC peripheral blood mononuclear cells
  • NK Natural Killer
  • ADCC activity of the molecule of interest can be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al. (USA) 95:652-656 (1998).
  • cysteine residue(s) may be introduced in the Fc region of the antibodies of the invention, thereby allowing interchain disulfide bond formation in this region.
  • the homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176: 1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities.
  • “Complement dependent cytotoxicity” or “CDC” refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (Clq) to antibodies (of the appropriate subclass) which are bound to their cognate antigen.
  • a CDC assay e.g., as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996), can be performed.
  • Antibody variants with altered Fc region amino acid sequences and increased or decreased Clq binding capability are described in U.S. Pat. No. 6,194,551B1 and WO99/51642. The contents of those patent publications are specifically incorporated herein by reference. See, also, Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
  • the antibody of the invention would be conjugated to a potent cytotoxic drug so as to mediate ADC, or would be modified so as to mediate efficient ADCC or CDC, as detailed above.
  • This cytotoxic antibody would be administered intratumourally in a sufficient amount for treating solid cancer in a subject in need thereof or for preventing metastasis to develop.
  • the “frequency” of a particular cell population in a given sample is herein understood as being the proportion of this particular cell population among the cells present in said sample. It can be measured by calculating the percentage of cells of this particular population (i.e., displaying the markers known to be shared by the cells of this population) present in said sample, among the total number of cells present in the tested sample, or among the cells of another particular cell population (e.g., in the context of the invention, among all DC cells or among CD45 + leukocytes). It can also be the number of cells belonging to the target population divided by the number of other cells, provided that said number of other cells is normalized between samples, so as to be comparable.
  • the “frequency” of the cells of the invention can be herein assimilated to the “concentration” or the “abundance” of the cells belonging to the target population of the invention, within a particular category of cells.
  • the term “frequency” as meant herein is therefore synonymous of the terms “proportion”, “percentage” or “concentration” which can be used interchangeably.
  • a “subject” which may be subjected to the methods described herein may be any of mammalian animals including human, dog, cat, cattle, goat, pig, swine, sheep and monkey. More preferably, the subject of the invention is human subject; a human subject can be known as a patient.
  • “subject” or “subject in need” refers to a mammal, preferably a human, that suffers from a solid cancer or is suspected of suffering from a solid cancer or has been diagnosed with solid cancer.
  • a “control subject” refers to a mammal, preferably a human, which is not suffering from a solid cancer, and is not suspected of suffering from solid cancer.
  • Prognosis herein means the prediction/determination/assessment of the risk of disease (in particular a cancer and/or a tumour) progression (or evolution, or development) in an individual. Prognosis includes the assessment of the future development of the subject’s condition and the possible chances of cure. The prognosis can be determined on the basis of observations and/or measurements, carried out using various tools.
  • stratification refers to the separation/classification of subjects into subgroups by disease (in particular a cancer and/or a tumour) severity.
  • the different subgroups include the subgroup of healthy subjects as well as different subgroups of subjects with a disease, classified according to the stage of disease progression/advancement/severity (e.g., WHO grade I, II, III or IV cancer; and/or metastatic or non-metastatic brain cancer).
  • “Monitoring” or “Follow-up” herein refers to the identification/assessment of the progression (or evolution, or development) of a disease (in particular a cancer and/or a tumour) in a subject.
  • Monitoring may be carried out on the basis of observations and/or measurements, using different tools, at different time intervals. Intervals may be regular or irregular. Their frequency depends on the cancer but also on the stage of cancer progression. It can range from a few days (e.g. in case of severe/advanced/severe disease and/or rapidly progressing cancer and/or exacerbation phase) to a few years (e.g. in case of early, mild or moderate cancer and/or slowly progressing cancer).
  • determining the outcome means the prediction/determination/assessment of the most probable evolution (or progression or development) of a cancer (in particular a cancer and/or a tumour) in a subject. “Determining the outcome” of the disease thus includes at least assessing the next stages that are most likely to be undergone by the subject, in terms of probability. More specifically, “determining the outcome of a solid tumour” includes, but is not limited to, the assessment of the probabilities (or chances), for a subject of switching to a metastatic form; and/or the assessment of the probabilities (or chances), for a subject of having or progressing towards a tumour and/or a metastatic tumour.
  • predicting the metastasis-associated risk” or “assessing the risk of switching to a metastatic form” means the prediction/determination/assessment of the probabilities (or the chances) of exacerbation (or aggravation, or intensification) of a cancer and/or a tumour, in particular the prediction/determination/assessment of the probabilities (or the chances) to switch from a non-metastatic to a metastatic form.
  • treating refers to reducing or ameliorating the symptoms of a disorder (e.g., solid cancer). It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
  • “treating” a disease in a subject or “treating” a subject having a disease refers to subjecting the subject to a pharmaceutical treatment, e.g., the administration of a drug, such that the extent of the disease is decreased or prevented. For examples, treating results in the reduction of at least one sign or symptom of the disease or condition. Treatment includes (but is not limited to) administration of a composition, such as a pharmaceutical composition, and may be performed either prophylactically, or subsequent or the initiation of a pathologic event. Treatment can require administration of an agent and/ or treatment more than once.
  • selecting a therapy or “selecting a treatment” or “selecting a drug” refers to the process of selecting (choosing, or deciding for, or opting for) the most appropriate therapy for a subject, in view of the symptoms (or signs) detected (observed and/or measured) in the subject, and/or in view of the subject himself, and the general knowledge in the medical field (preferably the medical field closest to the disease). Selecting a therapy include selecting the most appropriate therapy and may include also selecting the most appropriate administration mode and/or the most appropriate posology.
  • the terms “assessing the efficacy of a therapy” or “assessment of treatment efficacy” refers to the determination of the clinical status of a subject undergoing treatment (i.e. receiving a therapy).
  • the treatment may be preventive, for example in the case of predisposition to a disease, or it may be curative, for example in the case of a diagnosed disease.
  • the effectiveness of the treatment can be assessed by determining the condition of the subject at different time intervals.
  • the condition of the subject can be assessed before the first dose of treatment and then at regular (or irregular) intervals after the first dose (e.g. after each new dose of treatment). A comparison of the subject’s condition at these different intervals can then be made to identify any changes.
  • the patient’s condition can be assessed on the basis of observations and/or measurements made with different tools.
  • solid tumour or “solid cancer” to be prognosed or treated by means of the methods of the invention can be metastatic or not, notably selected in the group consisting of: squamous cell carcinoma, small-cell lung cancer, non-small cell lung cancer, glioma, gastrointestinal cancer, renal cancer, ovarian cancer, liver cancer, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, neuroblastoma, brain cancer, central nervous system cancer, pancreatic cancer, glioblastoma multiforme, cervical cancer, stomach cancer, bladder cancer, malignant hepatoma, breast cancer, colon carcinoma, head and neck cancer, gastric cancer, germ cell tumor, pediatric sarcoma, rhabdomyosarcoma, Ewing’s sarcoma, osteosarcoma, soft tissue sarcoma, sinonasal NK/T-cell lymphoma, myeloma, melanoma, multiple myeloma.
  • these solid tumours can be specifically lung cancer, malignant mesothelioma, bladder cancer, kidney cancer, testicular cancer, breast cancer, cancer of the upper aero-digestive tract, liver cancer, pancreas cancer, stomach cancer; colon cancer or ovarian cancer. More preferably, said solid tumour is a lung adenocarcinoma, such as a NonSmall Cell Lung Cancer. More preferably, said solid tumour is a breast cancer, such as triplenegative breast cancer (TNBC).
  • TNBC triplenegative breast cancer
  • the solid tumour or solid cancer to be prognosed or treated by means of the methods of the invention is chosen in the group consisting of : Bladder Carcinoma, Breast cancer, Cervical squamous cell carcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric cancer, Glioblastoma, Head-neck squamous cell carcinoma, Kidney renal clear cell carcinoma, Kidney renal papillary cell carcinoma, Liver hepatocellular carcinoma, Lung adenocarcinoma, Non-Small Cell Lung Cancer, Lung squamous cell carcinoma, Ovarian cancer, Pancreatic ductal adenocarcinoma, Pheochromocytoma and Paraganglioma, Rectum adenocarcinoma, Renal Cancer, Sarcoma, Stomach adenocarcinoma, Testicular Germ Cell Tumor, Thymoma, Thyroid carcinoma, Uterine
  • the solid tumour or solid cancer to be prognosed or treated by means of the methods of the invention is not a melanoma.
  • anti-cancer treatment or “anti-cancer therapy” or “therapy” designates any chemical or biochemical drug that can be used to treat a solid cancer. It is meant a substance which, when administered to a patient, treats or prevents the development of cancer in the patient.
  • an antitumor/cytotoxic antibiotic alkylating agents, antimetabolites, a topoisomerase inhibitor, a mitotic inhibitor, a platin based component, a specific kinase inhibitor, a hormone, a cytokine, an antiangiogenic agent, an antibody, a DNA methyltransferase inhibitor, a cancer vaccine, an immune checkpoint blocker and a vascular disrupting agent.
  • Said antitumor agent or cytotoxic antibiotic can for example be selected from an anthracycline (e.g.
  • doxorubicin doxorubicin, daunorubicin, adriamycine, idarubicin, epirubicin, mitoxantrone, valrubicin), actinomycin, bleomycin, mitomycin C, plicamycin and hydroxyurea.
  • Said alkylating agent can for example be selected from mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide, temozolomide busulfan, N-Nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU), semustine (MeCCNU), fotemustine, streptozotocin, dacarbazine, mitozolomide, thiotepa, mytomycin, diaziquone (AZQ), procarbazine, hexamethylmelamine and uramustine.
  • Said antimetabolite can for example be selected from a pyrimidine analogue (e.g. a fluoropyrimidine analog, 5-fluorouracil (5-FU), floxuridine (FUDR), cytosine arabinoside (Cytarabine), Gemcitabine (Gemzar®), capecitabine); a purine analogue (e.g. azathioprine, mercaptopurine, thioguanine, fludarabine, pentostatin, cladribine, clofarabine); a folic acid analogue (e.g. methotrexate, folic acid, pemetrexed, aminopterin, raltitrexed, trimethoprim, pyrimethamine) .
  • a pyrimidine analogue e.g. a fluoropyrimidine analog, 5-fluorouracil (5-FU), floxuridine (FUDR), cytosine arabinoside (Cytara
  • Said topoisomerase inhibitor can for example be selected from camptothecin, irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate and teniposide.
  • Said mitotic inhibitor can for example be selected from a taxane [paclitaxel (PG-paclitaxel and DHA-paclitaxel) (Taxol ®), docetaxel (Taxotere ®), larotaxel, cabazitaxel, ortataxel, tesetaxel, or taxoprexin]; a spindle poison or a vinca alkaloid (e.g. vincristine, vinblastine, vinorelbine, vindesine or vinflunine); mebendazole; and colchicine.
  • a taxane paclitaxel (PG-paclitaxel and DHA-paclitaxel) (Taxol ®), docetaxel (Taxotere ®), larotaxel, cabazitaxel, ortataxel, tesetaxel, or taxoprexin
  • a spindle poison or a vinca alkaloid e.g. vincri
  • Said platin based component can for example be selected from platinum, cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin and triplatin tetranitrate.
  • Said specific kinase inhibitor can for example be selected from a BRAF kinase inhibitor such as vemurafenib; a MAPK inhibitor (such as dabrafenib); a MEK inhibitor (such as trametinib); and a tyrosine kinase inhibitor such as imatinib, gefitinib, erlotinib, sunitinib or carbozantinib. Tamoxifen, an anti-aromatase, or an anti-estrogen drug can also typically be used in the context of hormonotherapy.
  • a BRAF kinase inhibitor such as vemurafenib
  • MAPK inhibitor such as dabrafenib
  • MEK inhibitor such as trametinib
  • a tyrosine kinase inhibitor such as imatinib, gefitinib, erlotinib, sunitinib or carbozantinib.
  • a cytokine usable in the context of an immunotherapy can be selected for example from IL-2 (Inter leukine-2), IL- 11 (Interleukine-11), IFN (Interferon) alpha (IFNa), and Granulocytemacrophage colony-stimulating factor (GM-CSF).
  • IL-2 Inter leukine-2
  • IL- 11 Interleukine-11
  • IFN Interferon alpha
  • GM-CSF Granulocytemacrophage colony-stimulating factor
  • Said anti-angiogenic agent can be selected for example from bevacizumab, sorafenib, sunitinib, pazopanib and everolimus.
  • the monoclonal antibody can be selected from a anti-CD20 antibody (anti-pan B-Cell antigen), anti-Her2/Neu (Human Epidermal Growth Factor Receptor- 2/NEU) antibody; an antibody targeting cancer cell surface (such as rituximab and alemtuzumab); a antibody targeting growth factor (such as bevacizumab, cetuximab, panitumumab and trastuzumab); a agonistic antibody (such as anti-ICOS mAb, anti-OX40 mAb, anti-4 IBB mAb); and an immunoconjugate (such as 90Y-ibritumomab tiuxetan, 1311- tositumomab, or ado-trastuzumab emtansine).
  • a anti-CD20 antibody anti-pan B-Cell antigen
  • anti-Her2/Neu Human Epidermal Growth Factor Receptor- 2/NEU
  • Said DNA methyltransferase inhibitor can for example be selected from 2'-deoxy-5-azacytidine (DAC), 5-azacytidine, 5-aza-2'- deoxycytidine, 1 -[beta]-D-arabinofuranosyl-5-azacytosine and dihydro-5 -azacytidine.
  • DAC 2'-deoxy-5-azacytidine
  • 5-azacytidine 5-aza-2'- deoxycytidine
  • 1 -[beta]-D-arabinofuranosyl-5-azacytosine dihydro-5 -azacytidine.
  • Said vascular disrupting agent can for example be selected from a flavone acetic acid derivative, 5,6-dimethylxanthenone-4- acetic acid (DMXAA) and flavone acetic acid (FAA).
  • DMXAA 5,6-dimethylxanthenone-4- acetic acid
  • FAA flavone acetic acid
  • chemotherapeutic drugs include a proteasome inhibitor (such as bortezomib), a DNA strand break compound (such as tirapazamine), an inhibitor of both thioredoxin reductase and ribonucleotide reductase (such as xcytrin), an immune checkpoint blocker and an enhancer of the Thl immune response (such as thymalfasin).
  • a proteasome inhibitor such as bortezomib
  • a DNA strand break compound such as tirapazamine
  • an inhibitor of both thioredoxin reductase and ribonucleotide reductase such as xcytrin
  • an immune checkpoint blocker such as thymalfasin
  • Said immune checkpoint blocker is typically an antibody targeting an immune checkpoint.
  • an immune checkpoint blocker can be advantageously selected from anti-CTLA4 (ipilimumab and Tremelimumab), anti-PD-1 (Nivolumab and Pembrolizumab), anti-PD-Ll (Atezolizumab, Durvalumab, and Avelumab), anti-PD-L2 and anti-Tim3 or combinations thereof.
  • said patients have been treated or will be treated with immunotherapy drugs such as anti-PD-1 and/or anti-PD-Ll drugs.
  • Said cancer vaccine can for example be selected from a vaccine composition comprising (antigenic) peptides; a Human papillomavirus (HPV) vaccine (such as Gardasil®, Gardasil9®, and Cervarix®); a vaccine stimulating an immune response to prostatic acid phosphatase (PAP) sipuleucel-T (Provenge®); an oncolytic virus and talimogene laherparepvec (T-VEC or Imlygic®).
  • HPV Human papillomavirus
  • PAP prostatic acid phosphatase
  • T-VEC oncolytic virus and talimogene laherparepvec
  • the treatment which can include several anticancer agents is selected by the cancerologist depending on the specific cancer to be prevented or treated.
  • anti-cancer treatment or “anti-cancer therapy” or “therapy” also designates any other treatment that was proven beneficial for treating cancer, namely radiotherapy, immunotherapy, or surgery.
  • the radiotherapy typically involves rays selected from X-rays (“XR”), gamma rays and/or UVC rays.
  • Dendritic cells are professional antigen-presenting cells that link innate and adaptive immunity and are critical for the induction of protective immune responses against pathogens. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and the adaptive immune systems. Dendritic cells are present in those tissues that are in contact with the external environment, such as the skin (where there is a specialized dendritic cell type called the Langerhans cell) and the inner lining of the nose, lungs, stomach and intestines. They can also be found in an immature state in the blood. Once activated, they migrate to the lymph nodes where they interact with T cells and B cells to initiate and shape the adaptive immune response. At certain development stages they grow branched projections, the dendrites that give the cell its name.
  • Gramulocytes are a type of leukocytes characterized by the presence of granules in their cytoplasm. The types of these cells are neutrophils, eosinophils, and basophils.
  • T cells or “T lymphocytes” are a type of lymphocyte that plays a central role in cell-mediated immunity. They can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface.
  • B cells or “B lymphocytes” are a type of lymphocyte in the humoral immunity of the adaptive immune system.
  • NK cells natural killer cells
  • BCR B-cell receptor
  • a cell “expresses CD207” (or CD la or any other biomarker) if CD207 (or CD la or any other biomarker) is present at a significant level on its surface (such a cell being also defined as a “CD207 + cell” (or a “CDla + cell”, etc.).
  • a cell expresses CD207 (or CD la or any other biomarker) if the signal associated to surface CD207 (or CDla or any other biomarker) staining (e.g. obtained with an antibody anti-CD207 coupled to a fluorescent marker) which is measured for said cell is superior to the signal corresponding to the staining of one cell being known as not expressing CD207 (or CDla or any other biomarker).
  • CD207 + cells are such that the ratio between the surface CD207- (or CDla- or any other biomarker) -associated signal measured for said cells and the surface CD207- (or CDla- or said other biomarker) -associated signal measured for cells being known as expressing CD207 (or CDla or said other biomarker) is superior or equal to 1.
  • Cells expressing CD207 (or CDla or said other biomarker) at their surface are well known in the art.
  • reference value refers to the expression level of a prognosis marker under consideration in a reference sample.
  • a "reference sample”, as used herein, means a solid cancer sample obtained from subjects, preferably two or more subjects, known to be suffering from solid cancer with a good prognosis.
  • the suitable reference expression levels can be determined by measuring the expression levels of said prognosis marker in several suitable subjects, and such reference levels can be adjusted to specific subject populations.
  • the reference value or reference level can be an absolute value; a relative value; a value that has an upper or a lower limit; a range of values; an average value; a median value, a mean value, or a value as compared to a particular control or baseline value.
  • a reference value can be based on an individual sample value such as, for example, a value obtained from a sample from the subject being tested, but at an earlier point in time. It can also be based on a sample from the subject being tested, taken from a non-cancerous tissue (i.e., a normal tissue of the same subject, adjacent to the tumour or not). The reference value can be based on a large number of samples, such as from population of subjects of the chronological age matched group, or based on a pool of samples including or excluding the sample to be tested.
  • antibody as used herein is intended to include monoclonal antibodies, polyclonal antibodies, and chimeric antibodies. Antibody fragments can also be used in the present diagnosis method. This term is intended to include Fab, Fab', F(ab')2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, and multimers thereof and bispecific antibody fragments. Antibodies can be fragmented using conventional techniques. For example, F(ab')2 fragments can be generated by treating the antibody with pepsin. The resulting F(ab')2 fragment can be treated to reduce disulfide bridges to produce Fab' fragments. Papain digestion can lead to the formation of Fab fragments.
  • the antibodies used in the method of the invention can be of different isotypes (namely IgA, IgD, IgE, IgG or IgM). They may be from recombinant sources and/or produced in transgenic animals. Conventional techniques of molecular biology, microbiology and recombinant DNA techniques are within the skill of the art. Such techniques are explained fully in the literature. Commercial antibodies recognizing specifically the antigens expressed by tumour cells can be furthermore used. Some of them are listed in the experimental part below (said list being however not exhaustive nor limitating).
  • antibodies can be detected by direct labeling with detectable markers.
  • unlabeled primary antibody can be used in conjunction with a labeled secondary antibody, comprising antisera, polyclonal antisera or a monoclonal antibody specific for the primary antibody.
  • Immunohistochemistry protocols and kits are well known in the art and are commercially available.
  • these antibodies are tagged with a detectable marker, preferably a fluorescent or a luminescent marker. Examples of detectable markers / labels include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorot[pi]azinylamine fluorescein, dansyl chloride or phycoerythrin
  • an example of a luminescent material includes luminol
  • examples of bioluminescent materials include luciferase, luciferin, and aequorin
  • suitable radioactive material include 125 I, 131 1, 35 S or 3 H.
  • the invention preferably does not relate to antibodies in natural form, i.e., they are not taken from their natural environment but are isolated or obtained by purification from natural sources or obtained by genetic recombination or chemical synthesis and thus they can carry “unnatural” amino acids as will be described below. They can also be multispecific, for example TandAb or Flexibody.
  • the antibodies When used for therapeutic purposes, the antibodies can be chimeric or humanized, or antigenbinding fragments which can be obtained by genetic engineering or by chemical synthesis.
  • chimeric antibody refers to an antibody containing a natural variable region (light chain and heavy chain) derived from an antibody of a given species in combination with constant regions of the light chain and of the heavy chain of an antibody of a species heterologous to said given species.
  • a “chimeric antibody”, as used herein is an antibody in which the constant region, or a portion thereof, is altered, replaced, or exchanged, so that the variable region is linked to a constant region of a different species, or belonging to another antibody class or subclass.
  • Chimeric antibody also refers to an antibody in which the variable region, or a portion thereof, is altered, replaced, or exchanged, so that the constant region is linked to a variable region of a different species, or belonging to another antibody class or subclass.
  • Such chimeric antibodies, or fragments of same can be prepared by recombinant engineering.
  • the chimeric antibody could be produced by cloning recombinant DNA containing a promoter and a sequence coding for the variable region of a non-human monoclonal antibody of the invention, notably murine, and a sequence coding for the human antibody constant region.
  • a chimeric antibody according to the invention coded by one such recombinant gene could be, for example, a mouse-human chimera, the specificity of this antibody being determined by the variable region derived from the murine DNA and its isotype determined by the constant region derived from human DNA.
  • humanized antibody refers to a chimeric antibody which contain minimal sequence derived from non-human immunoglobulin.
  • a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired specificity, affinity, and/or capacity.
  • donor antibody such as mouse, rat, rabbit or non-human primate having the desired specificity, affinity, and/or capacity.
  • framework (“FR”) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications may be made to further refine antibody performance, such as binding affinity.
  • a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin sequence, and all or substantially all of the FR regions are those of a human immunoglobulin sequence, although the FR regions may include one or more individual FR residue substitutions that improve antibody performance, such as binding affinity, isomerization, immunogenicity, etc.
  • the number of these amino acid substitutions in the FR are typically no more than 6 in the Heavy (H) chain, and in the Light (L) chain, no more than 3.
  • the humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • Figure 1 Spectral flow cytometric analysis of antigen presenting DC populations in 8 NSCLC patients.
  • A UMAP of singlet, live, CD45 + cells from normal adjacent and tumour samples of 4 representative NSCLC patients.
  • B UMAP of extracted MNPs showing delineation of cDCls, DC2+DC3s, CD123 + DCs (pDC and pre-DC) and monocytes/macrophages (MoMac).
  • C-D Identification and quantification of cDC2s and DC3s and
  • E DC3/cDC2 ratio between normal adjacent and tumour samples.
  • F RNA expression of CD207 and CD1A and protein expression of CD103 on the DC-VERSE.
  • Figure 3 Characterisation of the pathophysiological involvement of CD207 DC2+DC3s in human cancer patients.
  • B cDCl to CD207 DC2+DC3 ratio for patients from Bassez et al., with at least one CD207 DC2+DC3.
  • C Pearson correlations between the percentage of CD207 DC2+DC3s and total CD8 + T-cells (left), CD8 + TRMS (middle) or CD8 + TEMRAS (right).
  • D Pearson correlation between CD207 DC2+DC3s and CD8 + T-cells from flow cytometry analysis of tumours cells obtained from 8 NSCLC patients.
  • E Correlation map of DC population signatures (defined in the DC-VERSE) and of other signatures obtained from Ramos et al., (Nalio Ramos et al., 2022).
  • F Percentage of the CD207 DC2+DC3 signature-positive patients between Disease-Specific Survival (DSS) status in the seven TCGA cancer datasets. Deceased represents disease-specific death, and alive denotes disease-specific survival.
  • DSS Disease-Specific Survival
  • BRCA Kidney Renal Clear Cell Carcinoma
  • KIRC Lung Adenocarcinoma
  • LUSC Lung Squamous Cell Carcinoma
  • THCA Thyroid Carcinoma
  • DLBC Lymphoid Neoplasm Diffuse Large B-cell Lymphoma
  • UCEC Uterine Corpus Endometrial Carcinoma
  • G Kaplan-Meier plot of the overall survival (OS) of patients with different cancers whose tumour was sampled and analysed by bulk RNAseq prior to immune checkpoint blockade (ICB) treatment. Patients were separated based on high or low expression of DC populations mean gene signatures (left and middle panels) or based on the ratio of XCR1 to CD207 transcripts (right panel).
  • H Expression of CD207 + CD1A (Fragments Per Kilobase per Million) in patients with different cancer types, depending on their response to the following ICB treatments: anti-PDl monoclonal antibody for metastatic urothelial cancer, and, for the other cancer types: #1: cf.
  • Gating strategy to define DCs and the phenotype of CD207 DC2+DC3 in NSCLC spectral flow cytometry data.
  • A Gating strategy from singlets, live, CD45 + cells and projection of each gated population onto the MNP UMAP space.
  • B MNP UMAP annotation confirmed by protein expression.
  • C Gating of pDC and pre-DC within CD123 + DCs defined in Figure 1A- B.
  • D Gating of CD103 + “ZEB” and CDla + CD207 + DC2+DC3.
  • E Fold increase of CD207 + DC2+DC3s in tumour versus normal adjacent lungs.
  • F Expression of CD5 and CD14 by DC2+DC3 subsets defined in panel (D).
  • CDlc + eDCs could be broadly divided into CDP/pre-DC-derived cDC2s and CDP/pre-DC- independent DC3s, which include inflammatory CD14 + DC3s (Dutertre et al., 2019).
  • cDC2A and cDC2B subsets which we show here resemble Dutertre et al. CD5 + cDC2s and CD5 CD14 +/ ' DC3s, respectively, at both protein and RNA levels.
  • DC3s were initially proposed as being a subset of CDlc + “DC2s” that harbour pro-inflammatory CD14 + cells (Bourdely et al., 2020; Dutertre et al., 2019).
  • DC3 has also been used to describe cells (Di Pilato et al., 2021; Gerhard et al., 2020; Zilionis et al., 2019), that have an obvious transcriptomic alignment to mregDCs (Di Pilato et al., 2021 ; Maier et al., 2020; Zheng et al., 2017). Consequently, using the term “DC3” to describe these two fundamentally different populations can be confusing for researchers (Ginhoux et al., 2022). In an attempt to resolve this, the present inventors showed here how published signatures aligned to the DC populations identified here in the DC- VERSE.
  • the various nomenclature assigned to mregDCs included migratory/activated/A4A7P3/CCR7/“DC3”. Since the DC- VERSE considers several datasets across various diseases and tissues, the present analysis is one of the most in-depth and comprehensive analyses of antigen presenting DC heterogeneity. Therefore, to avoid any further confusion, it is proposed to use in the future the nomenclature used here.
  • the DC-VERSE allowed to investigate DC2+DC3 heterogeneity and profile antigen presenting DCs across steady state tissues and disease. By integrating a large number of cells, the DC- VERSE also allowed to automatically exclude/annotate senescent cells (that fell within the Low_nFeat. cl. #20), although lower quality cells were already excluded prior to integration. Another advantage of this approach was that focusing solely on DCs allowed reducing the data's global variance, which revealed discrete cell subsets during dimensionality reduction (PCA within the Seurat V3 pipeline followed by UMAP and unsupervised clustering).
  • the present inventors particularly focused on the changes of DC heterogeneity between healthy and tumour tissues. By doing so, they observed genes such as SPP1, which were highly expressed in tumour tissues mirroring findings also observed in monocytes and macrophages (Mulder et al., 2021), but also revealed a downregulation of genes such as the cDCl -specific CLEC9A gene that already pointed out to a reduction of cDCls’ density within human tumours (Kvedaraite and Ginhoux, 2022). Recently, an enrichment of “ISG + DC2s” was observed in the tumours of mice, which efficiently activate CD8 + T-cells, thus promoting anti-tumour immunity (Duong et al., 2021).
  • the present inventors also identified TF -primed DCs in human tumours, which were also increased in the majority of cancers compared to normal adjacent tissue. Additionally, the expansion of mregDCs and DC3s has been reported in lung cancer patients (Leader et al., 2021; Maier et al., 2020), which was extended to several cancers. They further confirmed this by flow cytometry in 7 out of 8 NCSLC patients. Of note, while Leader et al., observed an expression of CD1A and CD207 transcripts by tumour DC2+DC3s, the inventors were able to clearly delineate a discrete subset of CD2O7 + CD1A + DC2+DC3s (CD207 DC2+DC3s).
  • CD103 + " TB” and CD207 + CDla + DC2+DC3 populations could correspond to an activation “state” rather than an ontogenically distinct cell subsets since they both exhibit DC2 (CD5 + ) and DC3 (CD5 CD14 +/ ) phenotypes.
  • mregDCs which correspond to a mature (potentially migratory) “state” and not to a distinct DC subset.
  • mregDCs comprise both cDCls, DC2 and maybe DC3s that have engaged a common maturation gene expression program (Maier et al., 2020).
  • Tumour and healthy adjacent tissue from the lung as well as FFPE blocks were obtained from Non-Small Cell Lung Cancer patients following written informed consent (Marie Lannelongue Hospital, Paris) and ethical approval (N°ID-RCB: 2016-A00732-49). All subjects provided IRB-approved consent. Human tissues were cut into 0.5 cm squares and incubated with 0.8 mg/mL collagenase (Type IV, Worthington-Biochemical) in RPMI (PAA) with 10% FCS (AutogenBioclear) for 2 and 8 h, respectively, or when stated mechanically dispersed.
  • PAA RPMI
  • FCS AutogenBioclear
  • CD123-BUV395 (clone 7G3), HLA-DR-BV786 (clone L243), CD5-BV711 (clone UCHT2), CD3-BV650 (clone SP34-2), CD20-BV650 (clone 2H7), CD45-V500 (clone HI30), CD2-BV421 (clone RPA-2.10), CD45RA-FITC (clone 5H9), CD14-AlexaFluor700 (clone M5E2), all from BD Biosciences; CD163-BV605 (clone GHI/61), CDlc-PercP/Cy5.5 (clone L161), CD88-PE/Cy7 (clone S5/1), CD16-APC/Cy7 (clone 3G8), all from Biolegend; CD141-APC (clone 7G3), HLA-DR-BV786 (clone L243), CD5-BV711 (clone UCH
  • the primary and secondary antibodies used for immunofluorescence are summarized in the key resources table. Necrotic, serous, folded and blurred areas were excluded from image analyses.
  • the CD20/CD3/CD207/CD8 4-plex staining was performed manually using the OPAL tyramide system amplification (TSA) (Akoya Biosciences). Nuclei were stained with DAPI Solution (Thermofisher, 62248) at 2pg/ml for 5 minutes. After mounting with ProLongTM Glass Antifade Mountant (Thermofisher, P36980), the slides were scanned at 20X magnification using a Zeiss Axio scan Z1 device. Antibodies and TSA used are listed in this table: Algorithms for dimensionality reduction
  • DEGs Differentially expressed genes
  • DEG analyses were performed using the Seurat v3 package (Stuart et al., 2019). DEGs obtained from the “RNA” matrix of the Seurat object were calculated on normalised values with a logFC threshold of 0.25, and the threshold for false discovery is 0.05. The likelihood-ratio test for single-cell gene expression (bimodal test) was used, and correction for multiple testing was carried out using the Bonferroni method. For the generation of the DEG heatmap, pairwise DEGs were calculated for all possible combinations between LCH, LC and CD207 DC2+DC3. Uniquely expressed DEGs and shared DEGs between populations were plotted using the Seurat heatmap function.
  • the package pHeatmap was used as described above.
  • the signatures were obtained from various public datasets.
  • the DC-VERSE was split into the defined mega clusters in which we obtained the average gene expression of every mega cluster for all the genes present. Following this, the mean expression of the signature is calculated and plotted by the mega clusters in the heatmap.
  • GRNs gene regulatory networks
  • DERs Differentially expressed regulons
  • IP A Ingenuity Pathway Analysis
  • tumour and normal adjacent tissue areas were defined by a pathologist (G.G.). Within tumour, tumour nests and stromal areas were identified using the Halo 10 software (Indica labs) with a classifier based on examples of the two areas.
  • the density of positive cells/mm 2 : CD3 + , CD8 + , CD20 + , and CD207 + cells were quantified in the different zones with HalolO software (Indica labs) using the fitting counting algorithms.
  • the inventors recently performed a meta-analysis of human macrophages and monocytes sequenced from 41 published datasets across 13 tissues in health and disease (Mulder et al., 2021). They adopted a similar approach for eDCs, where datasets were first integrated tissue by tissue using the Seurat V3 pipeline, from which eDCs were then extracted and re-integrated into a UMAP space to generate the DC-VERSE (not shown). They used the Phenograph algorithm (Levine et al., 2015) to define clusters and calculated the DEGs and differentially expressed regulons (DERs) for all Phenograph clusters (cl. #) using the RNA matrix (not shown). Cl.
  • #20 consisted of cells with a relatively low nfeature_RNA (not shown) and cl. #15 was a minor population of 118 cells that were consequently not examined further (not shown). The inventors examined the expression of well-established signature genes and proteins (using CITE-seq data provided by Maier et al.) to broadly identify major DC subsets (not shown).
  • TCF4/AXL transcripts and CD45RA/CD123 protein expression identified pre-DCs; CADM1/CLEC9A transcripts and CD141/CD26 proteins identified cDCls; FCER1A/CD1C transcripts and CD33/CDlc proteins identified DC2+DC3s; BIRC3/LAMP3 transcripts and PD- L1/PD-L2 proteins identified mregDCs and PCNA/MKI67 transcripts identified proliferating eDCs (Prolif).
  • cl. #11 cells expressed T-cell specific membrane proteins, which likely represent T/DC cell doublets (not shown). They next implemented dendrogram clustering to understand the relationship of Phenograph clusters to one another and recognised twelve DC mega-clusters (not shown).
  • CD207 DC2+DC3s cl. #7), LTB DC2+DC3s (cl. #3 and #5), pre-DCs (cl. #19), cDCls (cl. #8 and #10), cDC2s (cl. #12, #13 and #17), DC3s (cl. #1, #4 and #9), mregDCs (cl. #14 & #16), IL1B DC2+DC3s (cl. #18), proliferating DCs (Prolif) (cl. #2 and #6) and T/DC doublets (cl. #11) [low nfeature (low nfeat.) cells (cl. #20) and a minor (cl.
  • cl. #17 was grouped as related to cDC2s, given the unique gene expression of IFN-related genes, they were considered as an independent megacluster that we called ZFV-primed DCs (not shown). Dendrogram clustering helped to define cDC2 and DC3 mega-clusters, alongside cDC2 and DC3 proteins from Maier etal.’s CITE-seq data (Maier et al., 2020), and cDC2 and DC3 gene signatures from Dutertre et al. (Dutertre et al., 2019) (not shown).
  • cDC2s and DC3s Given the close nature of cDC2s and DC3s, they further used CD5 and CD14 from CITE-seq data (Maier et al., 2020) to identify CD5 + cDC2s and CD14 + DC3s, which were then backgated onto the DC- VERSE to visualise their location within (not shown). They also highlighted cl.3 and cl.4 splenic cDC2A_Brown on the DC-VERSE, revealing that cl.3 corresponds to LTB DC2+DC3s while cells from cl.4 were detected within CD5 + cDC2s (not shown).
  • the DC-VERSE establishes conserved DC subsets and states across human tissues in health and disease
  • the inventors subsequently performed DEG analysis across mega-clusters to establish signature genes for each of these populations (not shown).
  • DC subsets mregDCs, pre-DCs, cDC2s, DC3s and cDCls
  • they also identified genes for less characterised/well-known DC subsets such as LTB and LST1 for LTB DC2+DC3s; CD I A, CD207 and HLA-DQB2 for CD207 DC2+DC3s; ISG15, IFI6, IFI44L and IFIT3 for // -primed DCs and finally AREG, IL1B, CCL17 and NFKB1 for IL IB DC2+DC3s.
  • DC subsets and states were detected in varying frequencies across healthy tissues, with some clusters such as mregDCs, LTB and CD207 DC2+DC3s detected only in tissues but not in blood (not shown).
  • DC2+DC3 heterogeneity in humans has also been recognised by Cheng et al. (Cheng et al., 2021).
  • the authors performed an in-depth analysis of DC2+DC3 subsets in various human cancer settings, describing six DC2+DC3 subsets (Cheng et al., 2021).
  • the inventors took advantage of the Azimuth tool, which allows the projection of a query dataset onto a reference map (Hao et al., 2021). After projecting the DC2+DC3 subsets onto the DC- VERSE, they could observe which mega-clusters these cells were assigned to (not shown).
  • DC- VERSE could filter out cells with a low nFeature_RNA as they mapped to the DC-VERSE cl. #20 (not shown).
  • the cDC2_7S'G75 cluster defined by Cheng et al. corresponded to the // -primed DC3s and the cDC2_ C7V7 cluster defined by Cheng et al., corresponded to DC3s.
  • cells with the signature of LTB DC2+DC3s and of CD207 DC2+DC3s corresponded to unique subsets of Cheng et al. ’s cDC2_CD 1A (not shown), highlighting the strength of the DC- VERSE to identify small discrete populations which might otherwise be missed.
  • the inventors performed a gene regulatory network analysis (SCENIC) to identify mega-cluster-specific regulons common to two datasets [Lung (Maier) and Tonsil (Cillo)] (Cillo et al., 2020; Maier et al., 2020), which adequately represented the UMAP space (not shown).
  • Regulons included SOX4 and KLF3 for pre-DCs, IRF8, KLF8, FOXB1, HOXA7 for cDCls, RXRA and RUNX3 for ('1)207 DC2+DC3s and ZEB1, IRF4, RELB for mregDCs.
  • the inventors performed a metadata analysis examining matched healthy and cancer tissues. They first compared DEGs between matched healthy and cancer tissue across all eDCs (not shown). To this end, they observed DEGs including SPP1, CD14, LTB, CD1A, BIRC3 and CD207 that were more highly expressed in the cancer setting, whereas CLEC9A (a cDCl specific gene) and CPVL were found to be enriched in the healthy tissues. As several of the DEGs corresponded to the DC-VERSE mega-cluster DEGs, they set out to examine how their relative proportions change across matched healthy and cancer tissues.
  • CD207 DC2+DC3s among proliferating DCs exhibited a 10.75-fold increase in the tumour relative to healthy tissue (not shown).
  • CD207 DC2+DC3s and cDCls comprised a greater percentage of proliferating cells in the tumour than in healthy (not shown).
  • MNPs mononuclear phagocytes
  • NSCLC non-small-cell lung carcinoma
  • MoMac monocyte/macrophages
  • CD207 DC2+DC3s were significantly increased in all examined tumour tissues compared to normal adjacent tissue. Given the expansion of these cells in tumour tissue, the inventors explored where the CD207 DC2+DC3s were located in tumour lesions from three triple-negative breast cancer (TNBC) patients and from two estrogen receptor-positive (ER) patients. To this end, they re-analysed Visium spatial data of breast cancer tumours (Wu et al., 2021), where they observed that contrary to most other myeloid cell subsets [that were often found in immune enriched/tertiary lymphoid structures (TLS) niches], CD207 DC2+DC3s were detected both in ‘invasive cancer+stroma’ and ‘normal+stroma+immune’ niches.
  • TNBC triple-negative breast cancer
  • ER estrogen receptor-positive
  • CD207 + DC2+DC3s were detected in tumour nests, particularly enriched in glandular structures (not shown).
  • Use of the HalolO software allowed to perform an unsupervised delineation of the stroma and tumour area only in 13 of the 16 stained cross-sections.
  • Quantitative analyses confirmed the significantly higher density of CD207 + DC2+DC3s in the tumour nests as compared to the tumour stroma, while CD3 + CD8 + T-cells were accumulating more in the tumour stroma than the tumour nests ( Figure 2C-D).
  • these data not only confirmed the intratumoural accumulation of CD207 DC2+DC3s but also allowed us to observe that these cells were embedded in between tumour cells, where T and B cells were mostly absent.
  • CD207 DC2+DC3s are associated with an unfavourable outcome in cancer
  • T-cell clonal expansion was only observed in patients with a cDCl to CD207 DC2+DC3 ratio >1 (both pre- and post-treatment) (Figure 3B).
  • T-cell clonality quantification requires single-cell TcR- sequencing, which cannot be used routinely due to cost and technical limitations.
  • the CD207 DC2+DC3s to cDCls ratio could become a mean to predict T-cell clonality within tumours.
  • the inventors next observed that the frequency of CD207 DC2+DC3s tended to negatively correlate with the frequency of CD8 + T-cells (Figure 3C).
  • CD207 DC2+DC3s inversely correlated with resident memory CD8 + T-cells (TRMS) ( Figure 3C) for patients without T-cell clonal expansion. This trend was extended to lung tumours scRNAseq data, where the percentage of CD207 DC2+DC3s trended to be higher in patients with a low frequency of CD8 + TRMS ( Figure 4B). Furthermore, CD207 DC2+DC3s strongly correlated with effector memory T-cells that re-express CD45RA (TEMRAS), which are terminally differentiated senescent and hypofunctional cells (Reading et al., 2018) ( Figure 3C).
  • TEMRAS effector memory T-cells that re-express CD45RA
  • the CD207 DC2+DC3 signature correlated negatively with T-cell subset signatures (CD8 + T-cells, CD8 + TRMS, exhausted T-cells and only for LUAD, Tregs) and with the cDCl signature, while the signatures of the other DC subsets did not show such negative correlation, except for the DC2 signature in the BRCA cohort which also negatively correlated only with the CD8 + TRM signature. Also, among the different T-cell subsets, the signature of CD8 + TRMS was the most negatively correlated with that of CD207 DC2+DC3s.
  • CD207 CD2+CD3 was strongly enhanced in patients suffering from metastatic Urothelial cancer and melanoma cancer that do not respond to the anti-PD-1 antibody treatment.
  • CD207 CD2+CD3 was strongly enhanced in patients suffering from NSCLC cancer that do not respond to several treatments (SRP1834555, SRP217040, ERP105482, etc). Also, the expression of CD207 CD2+CD3 was strongly enhanced in patients suffering from a glioblastoma that do not respond to the treatment (SRP155030).
  • CD207 DC2+DC3s could also serve as a prognostic factor alongside cDCls as the ratio of these cells predicted whether patients would develop a T-cell clonal expansion.
  • CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumour microenvironment. Cell 184, 4512-4530. e22.
  • Type I interferon activates MHC class I-dressed CD1 lb+ conventional dendritic cells to promote protective anti-tumour CD8+ T cell immunity. Immunity https://doi.Org/10.1016/j.immuni.2021.10.020.
  • Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell 185, 1189-1207. e25.
  • Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes. J Exp Med 152, 1070-1084.
  • Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci U S A 75, 5132-5136.
  • Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice. J Exp Med 157, 613— 627.
  • RNA-seq Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 356.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention propose un procédé efficace pour pronostiquer l'évolution d'un cancer solide chez un sujet en ayant besoin, par analyse de la fréquence d'un sous-ensemble particulier de cellules dendritiques ainsi que de leur nombre relatif par rapport à celui d'un autre sous-ensemble de cellules dendritiques dans un échantillon tumoral dudit sujet. Plus précisément, le procédé de l'invention comprend l'étape de détection et de quantification de la fréquence de cellules dendritiques CD207+ classiques de type 2 et 3 ("CD207+ DC2+DC3") dans un échantillon tumoral dudit sujet. Si la fréquence desdites cellules est élevée, en particulier dans le cœur tumoral, alors cela signifie que le sujet a un mauvais pronostic. Le procédé de l'invention comprend également le calcul à l'intérieur de la tumeur du rapport du nombre de cellules dendritiques classiques de type 1 (cDC1) au nombre de CD207+ DC2+DC3 pour prédire la clonalité de lymphocytes T dans la tumeur. En fait, les inventeurs ont ici établi que les CD207+ DC2+DC3 participent à la régulation de la cytotoxicité des lymphocytes T antitumoraux en limitant la clonalité des lymphocytes T et en altérant la réponse des lymphocytes T résidents du tissu (TRM) CD8+. Leur analyse révèle en outre que les CD207+ DC2+DC3 sont enrichis en biopsies de patients décédés ultérieurement par comparaison à des patients atteints de différents cancers solides. Les inventeurs proposent également de réduire l'abondance de ces cellules à l'intérieur du cœur tumoral, par exemple, par des médicaments appropriés, afin de limiter le développement de ladite tumeur solide chez le sujet.
PCT/EP2023/078773 2022-10-17 2023-10-17 Cellules dendritiques cd207 en tant que biomarqueur pour la progression tumorale et cible thérapeutique Ceased WO2024083790A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23793273.6A EP4605752A1 (fr) 2022-10-17 2023-10-17 Cellules dendritiques cd207 en tant que biomarqueur pour la progression tumorale et cible thérapeutique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22306572.3 2022-10-17
EP22306572 2022-10-17

Publications (1)

Publication Number Publication Date
WO2024083790A1 true WO2024083790A1 (fr) 2024-04-25

Family

ID=84044078

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/078773 Ceased WO2024083790A1 (fr) 2022-10-17 2023-10-17 Cellules dendritiques cd207 en tant que biomarqueur pour la progression tumorale et cible thérapeutique

Country Status (2)

Country Link
EP (1) EP4605752A1 (fr)
WO (1) WO2024083790A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1999051642A1 (fr) 1998-04-02 1999-10-14 Genentech, Inc. Variants d'anticorps et fragments de ceux-ci
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2004020487A (ja) * 2002-06-19 2004-01-22 Orient Cancer Therary:Kk ガンの検査法
US20040229297A1 (en) 2003-01-30 2004-11-18 Schering Corporation Methods for cancer prognosis and diagnosis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1999051642A1 (fr) 1998-04-02 1999-10-14 Genentech, Inc. Variants d'anticorps et fragments de ceux-ci
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2004020487A (ja) * 2002-06-19 2004-01-22 Orient Cancer Therary:Kk ガンの検査法
US20040229297A1 (en) 2003-01-30 2004-11-18 Schering Corporation Methods for cancer prognosis and diagnosis

Non-Patent Citations (60)

* Cited by examiner, † Cited by third party
Title
"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer", CANCER CELL, vol. 39, 2021, pages 1578 - 1593
BASSEZ, A.VOS, H.VAN DYCK, L.FLORIS, G.ARIJS, IDESMEDT, C.BOECKX, B.VANDEN BEMPT, M.NEVELSTEEN, I.LAMBEIN, K. ET AL.: "A single-cell map of intratumoural changes during anti-PD1 treatment of patients with breast cancer", NAT MED, vol. 27, 2021, pages 820 - 832, XP037452982, DOI: 10.1038/s41591-021-01323-8
BECHT, E.MCINNES, L.HEALY, J.DUTERTRE, C.-A.KWOK, I.W.H.NG, L.G.GINHOUX, F.NEWELL, E.W: "Dimensionality reduction for visualizing single-cell data using UMAP", NAT. BIOTECHNOL., 2018
BELL DIANA ET AL: "In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, whereas Mature Dendritic Cells Are Located in Peritumoral Areas", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 190, no. 10, 15 November 1999 (1999-11-15), pages 1417 - 1425, XP093040560, DOI: doi.org/10.1084/jem.190.10.1417 *
BELL, D.CHOMARAT, P.BROYLES, D.NETTO, G.HARB, G.M.LEBECQUE, S.VALLADEAU, J.DAVOUST, J.PALUCKA, K.ABANCHEREAU, J: "In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumour, Whereas Mature Dendritic Cells Are Located in Peritumoural Areas", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 190, 1999, pages 1417 - 1426
BÖTTCHER JAN P. ET AL: "The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity", TRENDS IN CANCER, vol. 4, no. 11, 29 September 2018 (2018-09-29), pages 784 - 792, XP093037892, ISSN: 2405-8033, DOI: 10.1016/j.trecan.2018.09.001 *
BOURDELY, P.ANSELMI, G.VAIVODE, K.RAMOS, R.N.MISSOLO-KOUSSOU, YHIDALGO, S.TOSSELO, J.NUNEZ, N.RICHER, W.VINCENT-SALOMON, A. ET AL.: "Transcriptional and Functional Analysis of CD1c+ Human Dendritic Cells Identifies a CD163+ Subset Priming CD8+CD103+ T Cells", IMMUNITY, vol. 53, 2020, pages 335 - 352
BROWN, C.C.GUDJONSON, H.PRITYKIN, Y.DEEP, D.LAVALLEE, V.-P.MENDOZA, A.FROMME, R.MAZUTIS, L.ARIYAN, C.LESLIE, C. ET AL.: "Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity", CELL, vol. 179, 2019, pages 846 - 863
CARON ET AL., J. EXP MED., pages 1191 - 1195
CHENG, S.LI, Z.GAO, R.XING, B.GAO, Y.YANG, Y.QIN, S.ZHANG, L.OUYANG, H.DU, P. ET AL.: "A pan-cancer single-cell transcriptional atlas of tumour infiltrating myeloid cells.", CELL, vol. 184, 2021, pages 792 - 809
CILLO, A.R.KURTEN, C.H.L.TABIB, T.QI, Z.ONKAR, S.WANG, T.LIU, A.DUWURI, U.KIM, S.SOOSE, R.J. ET AL.: "Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer", IMMUNITY, vol. 52, 2020, pages 183 - 199
CYTLAK, U.RESTEU, A.PAGAN, S.GREEN, K.MILNE, P.MAISURIA, S.MCDONALD, DHULME, G.FILBY, A.CARPENTER, B. ET AL.: "Differential IRF8 Requirement Defines Two Pathways of Dendritic Cell Development in Humans", ROCHESTER, NY: SOCIAL SCIENCE RESEARCH NETWORK, 2019
DI PILATO, M.KFURI-RUBENS, R.PRUESSMANN, J.N.OZGA, A.J.MESSEMAKER, M.CADILHA, B.L.SIVAKUMAR, R.CIANCIARUSO, C.WARNER, R.D.MARANGON: "CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumour microenvironment", CELL, vol. 184, 2021, pages 4512 - 4530
DUONG, E.FESSENDEN, T.B.LUTZ, E.DINTER, T.YIM, L.BLATT, S.BHUTKAR, A.WITTRUP, K.D.SPRANGER, S: "Type I interferon activates MHC class I-dressed CD1lb+ conventional dendritic cells to promote protective anti-tumour CD8+ T cell immunity", IMMUNITY, 2021, Retrieved from the Internet <URL:https://doi.org/10.1016/j.immuni.2021.10.020>
DUTERTRE, C.-A.BECHT, E.IRAC, S.E.KHALILNEZHAD, A.NARANG, V.KHALILNEZHAD, S.NG, P.Y.VAN DEN HOOGEN, L.L.LEONG, J.Y.LEE, B ET AL.: "Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells", IMMUNITY, vol. 51, 2019, pages 573 - 589
DYDUCH G ET AL.: "CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma", ADVANCES IN DERMATOLOGY AND ALLERGOLOGY, vol. 3, 9 May 2017 (2017-05-09), XP093037540, DOI: 10.5114/ada.2017.67845
DYDUCH GRZEGORZ ET AL: "CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma", ADVANCES IN DERMATOLOGY AND ALLERGOLOGY, vol. 3, 9 May 2017 (2017-05-09), POLAND, pages 233 - 239, XP093037540, ISSN: 1642-395X, DOI: 10.5114/ada.2017.67845 *
GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163
GERHARD, G.M.BILL, R.MESSEMAKER, M.KLEIN, A.M.PITTET, M.J.: "Tumour-infiltrating dendritic cell states are conserved across solid human cancers", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 218, 2020
GINHOUX, F.GUILLIAMS, M.MERAD, M: "Expanding dendritic cell nomenclature in the single-cell era", NAT REV IMMUNOL, vol. 22, 2022, pages 67 - 68, XP037682435, DOI: 10.1038/s41577-022-00675-7
GUILLIAMS, M.DUTERTRE, C.-A.SCOTT, C.L.MCGOVERN, N.SICHIEN, D.CHAKAROV, S.VAN GASSEN, S.CHEN, J.POIDINGER, M.DE PRIJCK, S. ET AL.: "Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species", IMMUNITY, vol. 45, 2016, pages 669 - 684, XP029755883, DOI: 10.1016/j.immuni.2016.08.015
GUILLIAMS, M.GINHOUX, F.JAKUBZICK, C.NAIK, S.H.ONAI, N.SCHRAML, B.U.SEGURA, E.TUSSIWAND, R.YONA, S: "Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny", NAT. REV. IMMUNOL., vol. 14, 2014, pages 571 - 578, XP055297705, DOI: 10.1038/nri3712
HAO, Y.HAO, S.ANDERSEN-NISSEN, E.MAUCK, W.M.ZHENG, S.BUTLER, A.LEE, M.J.WILK, A.J.DARBY, C.ZAGER, M. ET AL.: "Integrated analysis of multimodal single-cell data", CELL, vol. 184, 2021, pages 3573 - 3587
IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184
KIM, N.KIM, H.K.LEE, K.HONG, Y.CHO, J.H.CHOI, J.W.LEE, J.-I.SUH, Y.-L.KU, B.M.EUM, H.H. ET AL.: "Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma", NATURE COMMUNICATIONS, vol. 11, 2020, pages 2285
KVEDARAITE, E.GINHOUX, F: "Human dendritic cells in cancer", SCI IMMUNOL, vol. 7, 2022, XP093037424, DOI: 10.1126/sciimmunol.abm9409
LEADER, A.M.GROUT, J.A.MAIER, B.B.NABET, B.Y.PARK, M.D.TABACHNIKOVA, ACHANG, C.WALKER, L.LANSKY, A.LE BERICHEL, J. ET AL.: "Single-cell analysis of human non-small cell lung cancer lesions refines tumour classification and patient stratification", CANCER CELL, no. 21, 2021, pages 1535 - 6108
LEE, J.BRETON, G.OLIVEIRA, T.Y.K.ZHOU, Y.J.ALJOUFI, A.PUHR, S.CAMERON, M.J.SEKALY, R.-P.NUSSENZWEIG, M.C.LIU, K: "Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow", J. EXP. MED., vol. 212, 2015, pages 385 - 399
LEVINE, J.H.SIMONDS, E.F.BENDALL, S.C.DAVIS, K.L.AMIR EL, A.D.TADMOR, M.D.LITVIN, O.FIENBERG, H.G.JAGER, A.ZUNDER, E.R. ET AL.: "Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis", CELL, vol. 162, 2015, pages 184 - 197, XP055403730, DOI: 10.1016/j.cell.2015.05.047
LIU, K.VICTORA, G.D.SCHWICKERT, T.A.GUERMONPREZ, P.MEREDITH, M.M.YAO, K.CHU, F.-F.RANDOLPH, G.J.RUDENSKY, A.Y.NUSSENZWEIG, M: "In vivo analysis of dendritic cell development and homeostasis", SCIENCE, vol. 324, 2009, pages 392 - 397, XP055679378, DOI: 10.1126/science.1170540
MACKAY, L.K.MINNICH, M.KRAGTEN, N.A.M.LIAO, Y.NOTA, B.SEILLET, C.ZAID, A.MAN, K.PRESTON, SFREESTONE, D. ET AL.: "Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes", SCIENCE, vol. 352, 2016, pages 459 - 463
MAIER, B.LEADER, A.M.CHEN, S.T.TUNG, N.CHANG, C.LEBERICHEL, J.CHUDNOVSKIY, A.MASKEY, S.WALKER, L.FINNIGAN, J.P. ET AL.: "A conserved dendritic-cell regulatory program limits antitumour immunity", NATURE, vol. 580, 2020, pages 257 - 262, XP037525872, DOI: 10.1038/s41586-020-2134-y
MCINNES, L.HEALY, J.MELVILLE, J.: "UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction", ARXIV: 1802.03426, 2018
MULDER, K.PATEL, A.A.KONG, W.T.PIOT, C.HALITZKI, E.DUNSMORE, G.KHALILNEZHAD, S.IRAC, S.E.DUBUISSON, A.CHEVRIER, M. ET AL.: "Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease", IMMUNITY, vol. 54, 2021, pages 1883 - 1900
NAIK, S.H.SATHE, P.PARK, H.-Y.METCALF, D.PROIETTO, A.IDAKIC, A.CAROTTA, S.O'KEEFFE, M.BAHLO, M.PAPENFUSS, A. ET AL.: "Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo", NAT IMMUNOL, vol. 8, 2007, pages 1217 - 1226, XP055154963, DOI: 10.1038/ni1522
NALIO RAMOS, R.MISSOLO-KOUSSOU, Y.GERBER-FERDER, Y.BROMLEY, C.P.BUGATTI, M.NUNEZ, N.G.TOSELLO BOARI, J.RICHER, W.MENGER, L.DENIZEA: "Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer", CELL, vol. 185, 2022, pages 1189 - 1207
NUSSENZWEIG ET AL., STEINMAN AND WITMER, 1978
NUSSENZWEIG, M.C.STEINMAN, R.M.GUTCHINOV, B.COHN, Z.A.: "Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes", J EXP MED, vol. 152, 1980, pages 1070 - 1084
ONAI, N.OBATA-ONAI, A.SCHMID, MA.OHTEKI, T.JARROSSAY, D.MANZ, M.G: "Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow", NAT IMMUNOL, vol. 8, 2007, pages 1207 - 1216
OSZ, A.LANCZKY, A.GYORFFY, B: "Survival analysis in breast cancer using proteomic data from four independent datasets", SCI REP, vol. 11, 2021, pages 16787
P.DUTERTRE, C.-A.CHEN, J.GUNTHER, P.MCGOVERN, N.IRAC, S.E.GUNAWAN, M.BEYER, M.HANDLER, K.DUAN, K. ET AL.: "Mapping the human DC lineage through the integration of high-dimensional techniques", SCIENCE, vol. 356, 2017, XP055471908, DOI: 10.1126/science.aag3009
PARK, S.L.GEBHARDT, T.MACKAY, L.K.: "Tissue-Resident Memory T Cells in Cancer Immunosurveillance", TRENDS IN IMMUNOLOGY, vol. 40, 2019, pages 735 - 747, XP085747994, DOI: 10.1016/j.it.2019.06.002
QIAN, J.OLBRECHT, S.BOECKX, B.VOS, H.LAOUI, D.ETLIOGLU, E.WAUTERS, E.POMELLA, V.VERBANDT, S.BUSSCHAERT, P ET AL.: "A pan-cancer blueprint of the heterogeneous tumour microenvironment revealed by single-cell profiling", CELL RES, vol. 30, 2020, pages 745 - 762, XP037234467, DOI: 10.1038/s41422-020-0355-0
READING, J.L., GALVEZ-CANCINO, F., SWANTON, C., LLADSER, A., PEGGS, K.S., AND QUEZADA, S.A.: "The function and dysfunction of memory CD8+ T cells in tumour immunity", IMMUNOLOGICAL REVIEWS, vol. 283, 2018, pages 194 - 212, XP071456579, DOI: 10.1111/imr.12657
SHOPES, B, J. IMMUNOL., vol. 148, 1992, pages 2918 - 2922
STEINMAN, R.GUTCHINOV, B.WITMER, M.NUSSENZWEIG, M: "Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice", J EXP MED, vol. 157, 1983, pages 613 - 627
STEINMAN, R.M.COHN, Z.A: "IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 137, 1973, pages 1142 - 1162, XP009003685, DOI: 10.1084/jem.137.5.1142
STEINMAN, R.M.WITMER, M.D: "Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice", PROC NATL ACAD SCI U S A, vol. 75, 1978, pages 5132 - 5136
STUART, T.BUTLER, A.HOFFMAN, P.HAFEMEISTER, C.PAPALEXI, E.MAUCK, W.M.HAO, Y.STOECKIUS, M.SMIBERT, P.SATIJA, R: "Comprehensive Integration of Single-Cell Data", CELL, vol. 177, 2019, pages 1888 - 1902
TSUJI TENG KHMATSUZAKI JBATTAGLIA SSZENDER JBMILIOTTO AGNJATIC SBSHARA WMORRISON CDLELE S: "Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cance", ONCOTARGET, vol. 11, no. 27, 7 July 2020 (2020-07-07), pages 2669 - 2683, XP055887663, DOI: 10.18632/oncotarget.27666
VALPIONE SMUNDRA PAGALVANI ECAMPANA LGLORIGAN PDE ROSA FGUPTA AWEIGHTMAN JMILLS SDHOMEN N: "The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival", NAT COMMUN, vol. 12, no. 1, 2 July 2021 (2021-07-02), pages 4098
VAN DE SANDE, B.FLERIN, C.DAVIE, K.DE WAEGENEER, M.HULSELMANS, G.AIBAR, S.SEURINCK, R.SAELENS, W.CANNOODT, R.ROUCHON, Q. ET AL.: "A scalable SCENIC workflow for single-cell gene regulatory network analysis", NATURE PROTOCOLS, vol. 15, 2020, pages 2247 - 2276, XP037181096, DOI: 10.1038/s41596-020-0336-2
VILLANI, A.-C.SATIJA, R.REYNOLDS, G.SARKIZOVA, S.SHEKHAR, K.FLETCHER, J.GRIESBECK, M.BUTLER, A.ZHENG, S.LAZO, S. ET AL.: "Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.", SCIENCE, vol. 356, 2017, XP055422383, DOI: 10.1126/science.aah4573
WOLFF ET AL., CANCER RESEARCH, vol. 53, 1993, pages 2560 - 2565
WU, S.Z.AL-ERYANI, G.RODEN, D.L.JUNANKAR, S.HARVEY, K.ANDERSSON, A.THENNAVAN, A.WANG, C.TORPY, J.R.BARTONICEK, N. ET AL.: "A single-cell and spatially resolved atlas of human breast cancers", NAT GENET, vol. 53, 2021, pages 1334 - 1347, XP037557966, DOI: 10.1038/s41588-021-00911-1
ZHANG, Q.HE, Y.LUO, N.PATEL, S.J.HAN, Y.GAO, R.MODAK, MCAROTTA, S.HASLINGER, CKIND, D. ET AL.: "Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma", CELL, vol. 179, 2019, pages 829 - 845
ZHENG, C.ZHENG, L.YOO, J.-K.GUO, H.ZHANG, Y.GUO, X.KANG, B.HU, R.HUANG, J.Y.ZHANG, Q. ET AL.: "Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing", CELL, vol. 169, 2017, pages 1342 - 13 56
ZIEGLER-HEITBROCK, L.ANCUTA, P.CROWE, S.DALOD, M.GRAU, V.HART, D.N.LEENEN, P.J.M.LIU, Y.-J.MACPHERSON, G.RANDOLPH, G.J. ET AL.: "Nomenclature of monocytes and dendritic cells in blood", BLOOD, vol. 116, 2010, pages e74 - 80, XP009150973
ZILIONIS RAPOLAS ET AL: "Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species", IMMUNITY, vol. 50, no. 5, 9 April 2019 (2019-04-09), pages 1317 - e10, XP085694429, ISSN: 1074-7613, DOI: 10.1016/J.IMMUNI.2019.03.009 *
ZILIONIS, R.ENGBLOM, C.PFIRSCHKE, C.SAVOVA, V.ZEMMOUR, D.SAATCIOGLU, H.D.KRISHNAN, I.MARONI, G.MEYEROVITZ, C.V.KERWIN, C.M. ET AL.: "Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species", IMMUNITY, vol. 50, 2019, pages 1317 - 1334

Also Published As

Publication number Publication date
EP4605752A1 (fr) 2025-08-27

Similar Documents

Publication Publication Date Title
Steele et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer
CN110573180B (zh) 癌症治疗用药物组合物
JP7358047B2 (ja) 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー
Alvaro et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma
JP7429192B2 (ja) Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
Luo et al. Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy
EP4093513A1 (fr) Utilisations de biomarqueurs pour améliorer une immunothérapie
JP2016065082A (ja) 抗ｃｘｃｒ１組成物および方法
US10736963B2 (en) Methods for detecting tissue infiltrating NK cells
EP2756000B1 (fr) Anticorps monoclonal thérapeutiquement actif contre le polypeptide b7-h6
CN110850087A (zh) 用抗ccl25抗体和抗ccr9抗体检测癌症
EP4235179B1 (fr) Kit de détection, de quantification et/ou d&#39;isolement de cellules tumorales circulantes sur la base de l&#39;expression du marqueur cd321
JP2023526044A (ja) 免疫療法のための腫瘍バイオマーカー
EP2418222B1 (fr) Agent thérapeutique pour le traitement des maladies caractérisées par une prolifération néoplasique de plasmocytes
EP4605752A1 (fr) Cellules dendritiques cd207 en tant que biomarqueur pour la progression tumorale et cible thérapeutique
US11714089B2 (en) Combination of markers for diagnosing cancer
EP3962529A1 (fr) Méthodes de traitement du cancer à l&#39;aide de combinaisons d&#39;agents anti-cx3cr1 et d&#39;agents de blocage de points de contrôle immunitaires
KR20240103006A (ko) 점액성/원형 세포 지방육종 환자의 치료
Yang et al. A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
Marc Najjar et al. 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part
WO2024218260A1 (fr) Détection de macrophages associés à une tumeur dans le cancer du pancréas
Wang et al. CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses
WO2025186463A1 (fr) Agents se rapportant à l&#39;expression de cd61 sur des cellules immunitaires et leurs utilisations
JP2023535610A (ja) ガンを予防及び処置するための方法及び組成物
JP2012021795A (ja) 抗腫瘍剤の治療効果予測方法、抗腫瘍剤の治療効果予測キットおよび抗腫瘍剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23793273

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023793273

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023793273

Country of ref document: EP

Effective date: 20250519

WWP Wipo information: published in national office

Ref document number: 2023793273

Country of ref document: EP